Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category

Real Time Coverage @BIOConvention #BIO2019: What’s Next: The Landscape of Innovation in 2019 and Beyond. 3-4 PM June 3 Philadelphia PA

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Drug Delivery Platform Technology, Monoclonal Immunotherapy, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, tagged , , , , on June 3, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: What’s Next: The Landscape of Innovation in 2019 and Beyond. 3-4 PM June 3 Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

 

Speakers
responsible for VC at Pfizer
developing therapeutics based on GI microbiome to treat CNS
Xontogeny is an incubator
Focusing on building their tech platforms
Results from Clarivate
In 2018 most of deals were in CART area but now we are seeing more series A rounds that are on novel mechanisms as well as rare diseases.  US is still highest in venture capital series A but next is China. 10 of top ex US VC are from China, a whole lot of money.
Preclinical is very strong for US VC but China VC is focused on clinical.  First time this year we see US series A break above 100.  But ex US the series A is going down.  Although preclinical deals in US is coming back not like as good as in 2006.  But alot of > 1 billion $ deals.  Most of money into mAbs and protein therapy;  antisense is big and cell therapy is big too; small molecule not as much
ClearView Healthcare
Which innovation classes attracted VC in 2018?
  • Oncology drives a disproportionate focus could be driven by pharma focus on oncology; however there is some focus on neuro and infectious disease
  • therapeutic classes: shift to differentiated technology…. companies want technologic platforms not just drugs.  Nucleic Acid tech and antibody tech is high need platforms.  Startups can win by developing a strong platform not just a drug
There are pros and cons of developing a platform company versus a focused company.  Many VCs have a portfolio and want something to fit in so look for a focused company and may not want a platform company.  Pfizer feels that when alot of money is available (like now) platform investing is fine but when money becomes limited they will focus on those are what will be needed to fill therapy gaps.  They believe buy the therapy and only rent the platform.
Merck does feel the way Pfizer does but they have separate ventures so they can look and license platforms.  they are active in looking at companies with new modalities but they are focused on the money so they feel best kept in hands of biotech not pharma.
At Celgene they were solely focused on approvals not platforms.  Alot of money is required to get these platforms to market.  Concentration for platform companies should be the VCs not partnering or getting bought out by pharma.  it seems from panel speakers from pharma that they are waiting for science to prove itself and waiting for favorable monetary environments (easy money).  However it seems they (big pharma) are indicating that money is drying up or at least expect it too.
At Axial and with VCs they feel it is important to paint a picture or a vision at the early stage.
At Ontogeny, they focus on evaluating assets especially and most important, ThE MANAGEMENT TEAM.  There are not that many great talented drug development management teams he feels out there even though great science out there.

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: International Cancer Clusters Showcase June 3 Philadelphia PA

Posted in BioTechnology - Venture Creation, Venture Capital, Cancer - General, Cancer and Current Therapeutics, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Genomics, Conference Coverage with Social Media, tagged , , , , , , on June 3, 2019| Leave a Comment »

Real Time Coverage @BIOConvention #BIO2019: International Cancer Clusters Showcase June 3, Philadelphia PA

Reporter: Stephen J. Williams PhD @StephenJWillia2

Updated on 07/08/2021

https://cancerdiscovery.aacrjournals.org/content/early/2021/07/01/2159-8290.CD-20-1741

Updated on 07/08/2021

https://medicalxpress.com/news/2021-07-cancer-wider-access-immunotherapy.html

Larry Blandford PharmD from Precision Medicine Group gave introduction about development of precision oncology medicine.  Talked about value and value determination for partnerships.

Company Pitches:

Kernal Biologics: Preclinical immunotherapy company developing mRNA therapeutics.  Their therapy only have activity in p53 deficient cells (messenger 2.0).  They identified, by screening, multiple mRNAs that have oncoselectivity; ONC-333 is their lead mRNA active in AML and NSCLC.  Looking for 5.5M seed $

Vaccibody AS: Vaccine technology from Oslo University to target antigen to antigen presenting cells.  They are targeting the myocytes and dimerize the antigen to MHC.  Targeting melanoma, certain cervical cancers, and hemotologic cancers.  Technology based on identified neoantigens obtained from tumor biopsy.Three vaccines: VB10.neo  VB10.16 against HPV cervical

Chimeric Therapeutics: developing CART to solid malignancies against CLEC14 (tumor endothelial marker), may make tumor susceptible to hypoxia.  Targeting pancreatic cancer, prelim results in mice , efficacy of 15%, working on 3rd generation CART

Memo Therapeutics: Antibody therapeutics; based on Dropzylla single B cell sorting and subsequent screening for mAb.  Targeting checkpoint inhibitors on solid tumors;  have a new target other than PD1; target undisclosed on NK cells and T cells; Early stage have academic partners; seeking 20Million Swiss Francs

Takeda Oncology: Chris Hurff Senior Director Business Development; they depend on partnerships as they feel internal RD is less effective.  They are diversifying their portfolio from small molecules. They have over 200 partnerships (132 in Boston). They are focusing on heme, lung, and Immunooncology. Partnering model: CEI (center external innovation) deals with both academic and small biotechs.  They have numerous partners including Shatto and MD Anderson.

Read Full Post »

Real Time Coverage of BIO International Convention, June 3-6, 2019 Philadelphia Convention Center; Philadelphia PA

Posted in Alzheimer's Disease, Big Data, Bio Instrumentation in Experimental Life Sciences Research, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, FDA, FDA Regulatory Affairs, Foundations for supporting Science and Education, Health Economics and Outcomes Research, Healthcare costs and reimbursement, Institutional Capital Raised by Female Founders, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Pharmaceutical Analytics, REAL TIME Conference Coverage Twitter's Hashtags and Handles per Presentation/session, Trends in Global Economy, Venture Capital, tagged , , , , , , , , , , , on May 31, 2019| Leave a Comment »

Real Time Coverage of BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Please check daily on this OPEN ACCESS JOURNAL for updates on one of the most important BIO Conferences of the year for meeting notes, posts, as well as occasional PODCASTS.

 

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities.  The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world’s largest biotechnology exhibition – the BIO Exhibition.

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

 

Keynote Speakers INCLUDE:

Fireside Chat with Margaret (Peggy) Hamburg, MD, Foreign Secretary, National Academy of Medicine; Chairman of the Board, American Association for the Advancement of Science

Tuesday Keynote: Siddhartha Mukherjee (Author of the bestsellers Emperor of All Maladies: A Biography of Cancer and  The Gene: An Intimate History)

Fireside Chat with Jeffrey Solomon, Chief Executive Officer, COWEN

Fireside Chat with Christi Shaw, Senior Vice President and President, Lilly BIO-Medicines, Eli Lilly and Company

Wednesday Keynote: Jamie Dimon (Chairman JP Morgan Chase)

Fireside Chat with Kenneth C. Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co., Inc.

Fireside Chat: Understanding the Voices of Patients: Unique Perspectives on Healthcare

Fireside Chat: FDA Town Hall

 

ALSO SUPERSESSIONS including:

Super Session: What’s Next: The Landscape of Innovation in 2019 and Beyond

Super Session: Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Digital Health in Practice: A Conversation with Ameet Nathawani, Chief Digital Officer, Chief Medical Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Realizing the Promise of Gene Therapies for Patients Around the World

Super Session: Biotech’s Contribution to Innovation: Current and Future Drivers of Success

Super Session: The Art & Science of R&D Innovation and Productivity

Super Session: Dealmaker’s Intentions: 2019 Market Outlook

Super Session: The State of the Vaccine Industry: Stimulating Sustainable Growth

 

See here for full AGENDA

Link for Registration: https://convention.bio.org/register/

The BIO International Convention is literally where hundreds of deals and partnerships have been made over the years.

 

BIO performs many services for members, but none of them are more visible than the BIO International Convention. The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.

The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 1,500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.

In addition, we produce BIOtechNOW, an online blog chronicling ‘innovations transforming our world’ and the BIO Newsletter, the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

 

Membership with the Biotechnology Innovation Organization (BIO)

BIO has a diverse membership that is comprised of  companies from all facets of biotechnology. Corporate R&D members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. The majority of our members are small companies – 90 percent have annual revenues of $25 million or less, reflecting the broader biotechnology industry. Learn more about how you can save with BIO Membership.

BIO also represents academic centers, state and regional biotech associations and service providers to the industry, including financial and consulting firms.

  • 66% R&D-Intensive Companies *Of those: 89% have annual revenues under $25 million,  4% have annual revenues between $25 million and $1 billion, 7% have annual revenues over $1 billion.
  • 16% Nonprofit/Academic
  • 11% Service Providers
  • 7% State/International Affiliate Organizations

Other posts on LIVE CONFERENCE COVERAGE using Social Media on this OPEN ACCESS JOURNAL and OTHER Conferences Covered please see the following link at https://pharmaceuticalintelligence.com/press-coverage/

 

Notable Conferences Covered THIS YEAR INCLUDE: (see full list from 2013 at this link)

  • Koch Institute 2019 Immune Engineering Symposium, January 28-29, 2019, Kresge Auditorium, MIT

https://calendar.mit.edu/event/immune_engineering_symposium_2019#.XBrIDc9Kgcg

http://kochinstituteevents.cvent.com/events/koch-institute-2019-immune-engineering-symposium/event-summary-8d2098bb601a4654991060d59e92d7fe.aspx?dvce=1

 

  • 2019 MassBio’s Annual Meeting, State of Possible Conference ​, March 27 – 28, 2019, Royal Sonesta, Cambridge

http://files.massbio.org/file/MassBio-State-Of-Possible-Conference-Agenda-Feb-22-2019.pdf

 

  • World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON

https://worldmedicalinnovation.org/agenda-list/

https://worldmedicalinnovation.org/

 

  • 18th Annual 2019 BioIT, Conference & Expo, April 16-18, 2019, Boston, Seaport World Trade Center, Track 5 Next-Gen Sequencing Informatics – Advances in Large-Scale Computing

http://www.giiconference.com/chi653337/

https://pharmaceuticalintelligence.com/2019/04/22/18th-annual-2019-bioit-conference-expo-april-16-18-2019-boston-seaport-world-trade-center-track-5-next-gen-sequencing-informatics-advances-in-large-scale-computing/

 

  • Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

https://pharmaceuticalintelligence.com/2019/04/25/translating-genetics-into-medicine-april-25-2019-830-am-600-pm-the-new-york-academy-of-sciences-7-world-trade-center-250-greenwich-st-fl-40-new-york/

 

  • 13th Annual US-India BioPharma & Healthcare Summit, May 9, 2019, Marriott, Cambridge

https://pharmaceuticalintelligence.com/2019/04/30/13th-annual-biopharma-healthcare-summit-thursday-may-9-2019/

 

  • 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, May 17, 2019, Harvard Law School

http://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference

https://pharmaceuticalintelligence.com/2019/01/11/2019-petrie-flom-center-annual-conference-consuming-genetics-ethical-and-legal-considerations-of-new-technologies/

 

  • 2019 Koch Institute Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM  ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA

https://pharmaceuticalintelligence.com/2019/03/12/2019-koch-institute-symposium-machine-learning-and-cancer-june-14-2019-800-am-500-pmet-mit-kresge-auditorium-48-massachusetts-ave-cambridge-ma/

 

Read Full Post »

youngStartup Ventures & Leaders in Pharmaceutical Business Intelligence (LPBI) Group: discount code “LPBIVIP” @Registration

Posted in BioTechnology - Venture Creation, Venture Capital, Seeking Talent on May 24, 2019| Leave a Comment »

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is pleased to announce its sponsorship and invite you to attend the Dedicated Lifesciences/Healthcare Track at New York Venture Summit presented by youngStartup Ventures.

Reporter: Aviva Lev-Ari, PhD, RN

 

 

 

Official Logo of Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

 

Special discount.  Use discount code “LPBIVIP“ and receive 10% off the “early bird” rates. Early bird rates expire at the end of May.

 

>> Call for Top Lifesciences/Healthcare Innovators to present to leading Investors (details below).

 

New York

Venture Summit

July 9th & 10th 2019 | Convene | New York City

 

Where Innovation Meets Capital

 

 

Friends,

 

Come meet, interact and network with hundreds of VCs, Corporate VCs, angel investors, investment bankers and founders of venture backed, emerging and early stage companies on the Dedicated Lifesciences/Healthcare Track at the prestigious New York Venture Summit being held on July 9th & 10th 2019 at Convene, New York City.

 

Whether you’re a Lifesciences/Healthcare  startup seeking capital and exposure, or an investor seeking new deals, The New York Venture Summit presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, The New York Venture Summit is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage Lifesciences/Healthcare companies.

 

Partial list of VCs and Angels confirmed to speak and judge includes:

Jenny Abramson, Founder & Managing Partner, Rethink Impact | Nick Adams, Managing Partner & Co-Founder, Differential Ventures | Karine Agajanian, Senior Analyst, Anzu Partners | John Albright, Managing Partner, Relay Ventures | Andrew Aldrich, Principal, American Family Ventures | Liza Benson, Partner, Moderne Ventures | Lily Bernicker, Associate, Collaborative Fund | Laura Bock, Investor, QED Investors | Matt Brennan, Partner, General Catalyst Partners | Joel Brightfield, Principal, SixThirty | Ciara Burnham, Partner, QED Investors | Daniel Burstein, Managing Partner, Millennium Technology Value Partners | Don Burton, Founding & Managing Partner, LearnStart | Jason Cahill, Founder & Managing Director, McCune Capital | Alex Carusillo, Venture Associate, OCA Ventures | Benjamin Cukier, Founder, Centana Growth Partners | Ned Daoro, Senior Associate, Clocktower Technology Ventures | Soraya Darabi, General Partner, Trail Mix Ventures | Tyler Dean, Investor, Point72 Ventures | Parth Desai, Investor, Flare Capital Partners | Alan Du, Investor, Millennium Technology Value Partners | Tyler Durham, Principal, Schlumberger Ventures | Miriam Eaves, Venture Partner, BP Ventures | Kenny Estes, Co-Founder & Partner, West Loop Ventures | Dave Fan, Principal, Alumni Ventures Group | Michael Fanfant, Senior Associate, Runa Capital | Matt Fates, Founder & General Partner, Pulse Ventures | Sana Fathima, Investment Manager, Lockheed Martin Ventures | Lindsay Fitzgerald, Managing Director, American Express Ventures | Haley Fradkin, Investment Associate, Plum Alley Investments | Ben Freeberg, Senior Associate, Alpha Venture Partners | Kyle Fugere, Head of Ventures, dunnhumby Ventures | Anna Garcia, General Partner, Runway Venture Partners | Stephen Gilfus, Founder, Blackboard Inc. | Karim Gillani, General Partner, Luge Capital | Edward Greer, Corporate Technology Scout, Dow Ventures | John Gu, Investor, Spring Mountain Capital | Whitney Haring-Smith, Managing Partner, Anzu Partners | Will Hawkins, Senior Associate, Founder Collective | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Ann Hickey, Vice President, Town Hall Ventures | Kyle Howard-Johnson, Investor, Catalyst Investors | Vinay Iyengar, Investor, Bessemer Venture Partners | Deborah Jackson, Founder, Plum Alley Investments | Dhruv Jain, Investor, Bessemer Venture Partners | Del Johnson, Principal, Backstage Capital | Jay Karandikar, Venture Partner, New Crop Capital | Hana Khosla, Investor, Activant Capital | Avery Klemmer, Investor, FirstMark Capital | Jak Knowles, Vice President Venture Investments, Leaps by Bayer | Steve Konsek, Program Director, National Science Foundation | George Krautzel, Managing Partner, MissionOG | Ricky Lai, Senior Associate, Portag3 Ventures | Eddie Lee, Senior Associate, White Star Capital | Bion Ludwig, Partner, Savano Capital Partners | Coppelia Marincovic, Investment Manager, Solvay Ventures | Elizabeth McCluskey, Principal, Impact Engine | Shripal Meghani, Partner, Cleveland Clinic Ventures | Arpesh Mehta, Investment Director, DSM Venturing | Andrée-Lise Méthot, Founder & Managing Partner, Cycle Capital Management | Ed Michael, Co-founder and Managing Partner, LionBird Ventures | Sarah Millar, Associate, City Light Capital | Bá Minuzzi, General Partner, BABEL Ventures | Greg Neufeld, Partner, ValueStream Ventures | Jason Palmer, General Partner, New Markets Venture Partners | Matt Perlman, Principal, IA Capital Group | Victoria Pettibone, Managing Director, Astia Angels | Daniel Pianko, Partner, University Ventures | Adam Plotkin, Partner, ff Venture Capital | Jean-Noel Poirier, Managing Partner, Clean Energy Venture Group | Greg Pope, Principal, Anzu Partners | Alison Andrews Reyes, General Partner, 1843 Capital | Lisa Rhoads, Managing Director, Easton Capital | Douglas Roth, Managing Director, Connecticut Innovations | Boris Ryabov, Managing Partner, Bright Capital | Ernst Sack, Partner, Blue Bear Capital | Zak Schwarzman, Partner, MetaProp | Thomas Seo, Vice President, Citi Ventures | Connie Sheng, Founding Managing Partner, Nautilus Venture Partners | Jaidev Shergill, Managing Partner, Capital One Growth Partners | Zacary Sherman, Associate, Pereg Ventures | Nicole Shimer, Investment Associate, Insight Venture Partners | Raj Singh, Managing Partner, JetBlue Technology Ventures | Jean Sini, Angel Investor | Neil Swami, Principal, Catalyst Health Ventures | Erica Van, Associate, Charles River Ventures | Jamie M. Weston, Managing Director, Spring Mountain Capital | Anthony Xu, Partner, New Ground Ventures | Lisa Xu, Investor, FirstMark Capital | Wesley Yiu, Senior Associate, Triphammer Ventures | Chris Young, Partner, Revel Partners | Katherine Zamsky, Managing Partner, Carbon Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Greg Ziac, General Partner, NMT Capital | Chris Zock, Managing Director , Sandbox Insurtech Ventures and many more.

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence Group has made special arrangement for our network to receive a special discount, currently 10% off the existing “early bird” savings. Early bird rates expire at the end of May.

This conference will be attended by the best people in the industry. Please register early to avoid disappointment. 

 

Register Today & Save Click here.   

(Use promo code “LPBIVIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking. 

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators from the Technology, Life Sciences/Healthcare, CleanTech and Fintech sectors will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for our Seed stage track.

 

We look forward to seeing you there. 

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

&

youngStartup Ventures

Read Full Post »

MIXiii-BIOMED 2019 – The 18th National Life Science & Technology Week, May 14-16, 2019, David InterContinental, Tel Aviv, Israel

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital on May 13, 2019| Leave a Comment »

MIXiii-BIOMED 2019 – The 18th National Life Science & Technology Week, May 14-16, 2019, David InterContinental, Tel Aviv, Israel

 

 

Daily Program

NB: Please check program on site in case of last minute changes.

Time slots in blue text indicate Company Presentations. Click on company name to view abstract.

14 May 2019

+
09:30  –  11:20
Hall A

Opening Session

09:30-10:00 Welcome by Conference Chairpersons:
Ruti Alon, Founder and CEO, Medstrada
Ora Dar, PhD, Israel Innovation Authority
Nissim Darvish, MD, PhD, Senior Managing Director, Orbimed Advisors

10:00-10:40 Robert C. King, PhD, Partner at Goldman Sachs International and Global Vice Chairman, Investment Banking Division: “Current Developments in Healthcare Capital Markets and M&A”

10:40-11:20 Barry Greene, President, Alnylam Pharmaceuticals: “Nobel Prize-Winning Science to First Approved RNAi therapeutic”

+
11:20  –  11:50

Coffee Break

+
11:50  –  17:40
Hall A

Gene Editing and Gene Therapy: The Next Frontier in Human Health

Co-chairs: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx; Stephen Squinto, PhD, Interim CEO, Passage Bio

11:50-11:55 Opening by Co-chairs

11:55-12:20 Adi Barzel, PhD, Senior Lecturer, Department of Biochemistry at Tel Aviv University; Co-Founder of LogicBio Therapeutics, Inc.; President of the Israeli Society of Gene and Cell Therapy: “Principles of Gene Editing; CRISPR in B Cells Fighting AIDS”

12:20-12:40 Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH: “Novel Approaches for Antibody-targeted Intracellular Delivery of Large Nucleic Acids incl. CRISPR Mediated Gene Editing Modules”

12:40-13:00 Prof. Nadav Ahituv, PhD, Department of Bioengineering and Therapeutic Science, University of California San Francisco: “CRISPRa Therapeutics for Haploinsufficient Disease”

13:00-13:20 Rachel Haurwitz, PhD, Co-founder, President and CEO, Caribou Biosciences

13:20-13:35 Kyle Chiang, PhD, VP Product Strategy, LogicBio Therapeutics: “In Vivo Genome-editing for Rare Pediatric Diseases”

13:35-13:50 David Baram, PhD, Chief Executive Officer, Emendo Bio Inc: “Emendo Biotherapeutics – High Precision Gene Editing with Next Generation CRISPR Nucleases”

13:50-15:20 Lunch Break

15:20-15:45 Ronald G. Crystal, MD, Founder, LEXEO Therapeutics and Chair, Department of Genetic Medicine, Weill Cornell Medical College: “Gene Therapy for CNS Disorders”

15:45-16:05 Stephen Squinto, PhD, Interim CEO, Passage Bio: “Passage Bio: Developing Transformative Genetic Medicines for Rare Monogenic CNS Diseases”

16:05-16:25 Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx; “Using Gene Therapy for the Treatment of Rare Genetic Liver Disease”

16:25-16:40 Trevor Martin, PhD, CEO and Co-Founder, Mammoth Biosciences: “The Next Generation of CRISPR Tools”

16:40-16:55 Dalia El-Ani, PhD, Chief Executive Officer, CRISPR Stem & Therapeutics: “CRISPR: A Novel Gene Therapy to Protect the Heart from Acute Ischemic Damage”

16:55-17:40 “Panel Discussion
Panelists:
Ronald G. Crystal, MD, Founder, LEXEO Therapeutics and Chair, Department of Genetic Medicine, Weill Cornell Medical College
Rachel Haurwitz, PhD, Co-founder, President and CEO, Caribou Biosciences
Prof. Nadav Ahituv, PhD, Department of Bioengineering and Therapeutic Science, University of California San Francisco
Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx
Stephen Squinto, PhD, Interim CEO, Passage Bio

+
11:50  –  17:25
Hall B

Transforming Medicine: Artificial Intelligence and Digital Health

Co-chairs: Anat Naschitz, Managing Director, OrbiMed Advisors; Allen Kamer, Managing Partner, OurCrowd Qure

11:50-11:55 Opening by Co-chairs

11:55-12:20 Don Mathis, General Manager, Growth, Comcast NBCUniversal: “Changing Healthcare at Scale: How AI is Enabling Transformation”

12:20-12:45 Elliot Menschik, MD, PhD, Global Head Healthcare and Lifescience Startups, Amazon: “Democratizing AI/ML Capabilities and Accelerating their Impact on Healthcare”

12:45-13:00 Leif E. Pedersen, CEO, Dassault Systemes BIOVIA: “Real Life Examples of BioPharma Leveraging AI and Machine Learning”

13:00-13:15 Doron Behar, MD, PhD, CEO, Igentify: “An End-to-end & Scalable Digital Platform Designed for Web-assisted Genetic Counselling”

13:15-13:30 Yaron Gurovich, CTO, FDNA: “Hype vs. Hope: Using AI to Detect Disease”

13:30-13:45 Itay Bengad, CEO, MDGO: “Your Car Knows your Injuries”

13:50-15:20 Lunch Break

15:20-15:40 Avinatan Hassidim, Head of TLV Research, Google: “How Google uses Machine Learning for Medical Research”

15:40-15:55 Ziv Ofek, Founder and CEO, MDClone: “Democratizing Healthcare Data – today and Tomorrow”

15:55-16:10 Hadas Bitran, Head of Healthcare Israel, Microsoft: “Microsoft – Healthcare Innovation”

16:10-16:25 Tamara Mansfeld, Global Innovation Lead, Pfizer: “AI in Drug Discovery”

16:25-16:40 David Harel, Founder and CEO, CytoReason: “Machine Learning for Drug Discovery and Development”

16:40-16:55 Avi Veidman, Founder and CEO, Nucleai: “Harnessing AI for Pathology”

16:55-17:10 Ariel Beery, Founder and CEO, MobileODT: “Using Augmented Reality at the Point of Care to Eliminate Cervical Cancer”

17:10-17:25 Micah Pearlman, COO, Biolojic Design: “Making the Intractable Tractable: Designing Multi-Functional, Epitope Specific Antibodies using Machine Learning”

+
11:50  –  17:25
Hall C

Disruptive and Advanced Medical Devices

Co-chairs: Irit Yaniv, MD, General Partner, Accelmed; Ron Ginor, MD, Venture Partner, OrbiMed Advisors, L.L.C

11:50-11:55 Opening by Co-chairs

11:55-12:10 Bruce R. Rosengard, MD, VP, Global External Innovation, Johnson and Johnson Medical Devices: “Market Perspective”

12:10-12:25 Oren Goldshtein, Vectorius Medical Technologies: “Transforming Heart Failure Treatment with the World’s First In-heart Microcomputer”

12:25-12:40 Ofri Vaisman, COO, Bluewind Medical: “Bluewind Medical Renova System – Neurostimulation Therapy for Over Active Bladder”

12:40-12:55 Ron Aginsky, President, FUSMobile: “Non-Invasive Procedure for Interventional Pain Managment Treatment”

13:00-13:15 Nicholas Pachuda, WW Vice President, Orthopedic Innovation, J&J Medical Devices: “Field Specific – Orthopedics”

13:15-13:30 Yehiel Tal, CEO, Collplant Ltd, “rhCollagen – the Ideal Building Block for Regenerative Medicine”

13:30-13:45 Boaz Behar, CEO, Digma Medical: “Restoring Glycemic Control in Patients with T2D”

13:50-15:20 Lunch Break

15:20-15:35 John J. Smith, MD, Partner, Hogan Lovells: “Regulatory Perspective”

15:35-15:50 Nitai Hanani, CEO, Paragate Medical: “Implantable Peritoneal Ultrafiltration Device for Fluid Overload Treatment”

15:50-16:05 David Israeli, CEO, Magenta Medical: “Minimally-Invasive Blood Pumps for the Treatment of Acute Heart Failure”

16:05-16:20 Prof. Joel V. Brill, MD, FACP, Chief Medical Officer, Predictive Health. LLC: “Reimbursement Perspective”

16:20-16:35 Yoram Solberg, MD, PhD, VP Clinical Affairs, Brainsgate: “Spheno Palatine Ganglion Stimulation for Treatment of Acute Ischemic Stroke”

16:35-16:50 Nathalie Gilat, Senior Director, Nyxoah: “Nyxoah – Sleep Apnea Healthtech Company”

16:50-17:05 Shai Policker, Medex Exlerator, “Incubator Perspective”

17:05-17:20 Eric Tansky, Managing Director, Oppenheimer & Co. Inc.: “Funding Perspective”

17:20-17:25 Closing by Co-chairs

15 May 2019

+
09:30  –  11:40
Hall A

Plenary Session

09:30-09:50 Amy W. Schulman, Managing Partner, LS Polaris Innovation Fund and Polaris Partners: “Building Early Stage Companies within the Biotech Ecosystem: Challenges and Opportunities”

09:50-10:10 Aharon Aharon, CEO, Israel Innovation Authority: “Bio-convergence – the Future of Israeli Healthtech”

10:10-11:00 Corporate Panel: Innovative Biotech/Large Companies/Capital: What’s the Right Formula to Bring Products to Patients?
Moderator: Francois Maisonrouge, Senior Managing Director, Evercore Partners
Panelists:
Fiona de Hemptinne, Venture Partner, UCB Ventures
Miriam Frieden, PhD, MBA, VP of Search and Evaluation, Novo Nordisk
Laurent Choppe, DVM, Managing Partner, Cukierman & Co. Life Sciences
Zafrira Avnur, PhD, CSO & Partner, VP Quark Venture Inc.
Tina Xu, Vice President of Information Technology and Head of Business Innovation, AstraZeneca China

11:00-11:40 Todd Brinton, MD, Corporate Vice President, Advanced Technology and Chief Scientific Officer, Edwards Lifesciences:“Investing in Innovation”

 

+
11:40  –  12:10

Coffee Break

+
12:10  –  17:25
Hall A

Prevention and Rehabilitation: Should the Underdog Begin Barking?

Chair: Naomi Gefen, Deputy Director General, ALYN Hospital

Opening Session

12:10-12:25 Maurit Beeri, MD, Director General, ALYN Hospital: “From Prevention to Rehabilitation”

12:25-12:45 Yoav Medan, PhD: “The Technology Augmented Homo Sapiens“

Circle of Life: Prevention and Rehab for all ages

12:45-13:05 Sagit Arbel-Alon, MD, Deputy Director, Reuth Medical & Rehabilitation Hospital: “Geriatric Rehabilitation”

13:05-13:20 Rafi Fischer, Director of Media Communications, OrCam Technologies: “OrCam Technologies – AI-Driven Artificial Vision”

13:20-13:35 Or Retzkin, CEO & Co-founder; EyeControl: “EyeControl: Inspiring Communication”

13:35-13:55 Itamar Offer, MD, MPA, CEO, Sabar Health: “Rehabilitation at Home”

13:55-14:10 Yotam Drechsler, CEO, BrainQ technologies: “BCI Based Stimulation Device- BQ (BrainQ technologies)”

14:10-15:40 Lunch Break

15:40-15:55 Maurit Beeri, MD, Director General, ALYN Hospital: “Pediatric Rehabilitation”

15:55-16:10 Yotam Bahat, CEO, SENSERUM: “SENSERUM – VR for Clinical Use”

Taking Rehab to Another Level – Enabling Meaningful Participation in the Community and Workplace

16:10-16:25 Daniel Barel, CEO, SoftWheel: “SoftWheel – Innovative Technology for Mobility Solutions”

16:25-16:50 Yaron Galitzky, General Manager, Devices & Accessories, Microsoft; “Xbox Adaptive Controller”

16:50-17:15 Ziv Shilon, Co-founder, COO, 6Degrees: “Be the Hero of your Own Story”

Closing Session:
17:15-17:25 Naomi Gefen, Deputy Director General, ALYN Hospital: “The Future of Technology in Rehab”

+
12:10  –  17:25
Hall B

Tango of the Two: Academia and Industry

Co-chairs: Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University; Yaron Daniely, PhD, CEO, Yissum

12:10-12:30 Jeroen Tas, Chief Innovation & Strategy Officer, Philips

12:30-12:45 Prof. Yaakov Nahmais, PhD, Director, Grass Center for Bioengineering, The Hebrew University of Jerusalem: “Sensor-driven Leap in Drug Development on a Chip” 

12:45-13:00 Arnaldo Mayer, PhD, VP, R&D, Voxellence: “Voxellence: AI-powered Radiology”

13:00-13:15 Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University: “Monitoring Sleep Stages at Home”

13:15-13:45 Panel discussion: Lessons Learnt by Researchers
Moderator: Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University
Panelists
Prof. David Mirelman, PhD, Weizmann Institute of Science
Prof. Gal Markel, MD, PhD, Tel Aviv University
Prof. Daniel Offen, PhD, Tel Aviv University
Prof. Yaakov Nahmais, PhD, Director, Grass Center for Bioengineering, The Hebrew University of Jerusalem

13:45-14:00 Eran Stark, MD, PhD, Sackler Faculty of MedicineTel Aviv University: “Penetrating Neural Probes”

14:00-14:15 Giora Davidovits, President and CEO, Savicell: “A Revolutionary Liquid Biopsy, Immunometabolism Platform for High Accuracy, Early Stage Diagnosis of Diseases”

14:10-15:40 Lunch Break

15:40-15:55 Prof. Tal Dvir, PhD, Tel Aviv University: “Printed Heart”

15:55-16:10 Tomer Behor, CEO, RenewSenses: “RenewSenses – Conveying Vision Through Sound”

16:10-16:25 Chen Levin, CEO, Xact Robotics Ltd: “XACT Robotics – XACTly on Target Every Time”

16:25-16:40 Uzi Sofer, Alpha TAU Medical: “First Alpha-radiation Cancer Treatment for Solid Tumors”

16:40-16:55 Tamar Ben-Yedidia, PhD, CSO, BiondVax Pharmaceuticals Ltd: “Update of the Pivotal, Clinical Efficacy, Phase 3 trial of BiondVax’s M-001 Universal Influenza Vaccine”

16:55-17:45 Panel Discussion: It Takes a Village: Boosting the Volume and Quality of Academic Entrepreneurship
Moderator: Yaron Daniely, PhD, CEO, Yissum
Panelists:
Aviv Zeevi, PhD, VP, Technology Infrastructure Division, Israel Innovation Authority
Kelly Krajnik, Senior Manager, Devices, Diagnostics, Mayo Clinic Ventures
Regine Shevach, Managing Director at Inter-Lab, an affiliate of Merck KGaA
Yair Schindel, MD, Co-Founder & Managing Partner, aMoon
Shai Policker, CEO, Medex Xelerator LP

+
12:10  –  17:40
Hall C

New Modalities of Cell Therapies: Revolutionizing the Way We Treat Diseases

Co-chairs: Aya Jakobovits, PhD, Founder, Director, Adicet Bio; Erez Chimovits, Senior Managing Director, OrbiMed Advisors

12:10-12:15 Opening remarks by Co-chairs

12:15-12:40 Aya Jakobovits, PhD, Founder, Director, Adicet Bio: “Adoptive Cell Therapy 3.0”

12:40-13:05 Carl L. Gordon, PhD, Managing Partner, OrbiMed Advisors: “The Cell Therapy Field has already Generated some of the Best Returns in Biotechnology, and the Best is Yet to Come, Based on Enhanced Cell Therapy Technologies”

13:05-13:20 Prof. Angel Porgador, PhD, Ben-Gurion University: “Natural Killer (NK) Cells in Cancer Immunotherapy”

13:20-13:35 Michal J. Besser, PhD, Head of Laboratory, Ella Lemelbaum Institute for Immuno Oncology & Director, Wohl GMP Facility, Sheba Medical Center; Assistant Professor, Dept. of Microbiology and Immunology, School of Medicine, Tel Aviv University: “Clinical Experience with In-house Produced CAR T Cells”

13:35-13:50 Stewart Abbot, PhD, Chief Operating Officer, Adicetbio: “Off-the-shelf, Engineered Gamma Delta T-cell Therapies”

13:50-14:05 Merav Beiman, PhD, CEO, ImmPACT-Bio: “Next Generation CAR-T Engineering Solving the ‘On-Target’ ‘Off-Tumor’ Issue towards Broader, Safer and Effective CAR-T Therapies”

14:05-14:10 Aya Jakobovits, PhD, Founder, Director, Adicet Bio: “Session #1 Summary”

14:10-15:40 Lunch Break

15:40-15:55 Yoav Ben Ya’acov, CEO, CTG Pharma: “CTG Pharma- Safe CAR T Therapy for Solid Tumors”

15:55-16:10 Amy W. Schulman, Executive Chair, SQZ Therapeutics: “SQZ Biotech: Unleashing the Power of Cells”

16:10-16:25 Julian Adams, PhD, Chief Executive Officer, Gamida Cell: “Ex- vivo Expansion of Natural Killer (NK) Cells to Treat B-Cell Lymphoma and Multiple Myeloma”

16:25-16:40 Shmulik Hess, CEO, Enlivex Therapeutics R&D LTD: “Enilvex Therapeutics, Immune Rebalancing”

16:40-17:40 Panel Discussion: “The Path for Effective and Accessible Cancer Cell Therapy”
Panelists:
Amy W. Schulman, Executive Chair, SQZ Therapeutics
Aya Jakobovits, PhD, Founder, Director, Adicet Bio
Carl L. Gordon, PhD, Managing Partner, OrbiMed Advisors
Stewart Abbot, PhD, Chief Operating Officer, Adicet
Julian Adams, PhD, Chief Executive Officer, Gamida Cell

 

16 May 2019

+
09:30  –  10:50
Hall A

Plenary Session

09:30-10:10 Tom Sudow, Director, Business Development, Cleveland Clinic Innovations; Mark D. Stovsky, MD, MBA, FACS, Senior Director, Emerging Business, Cleveland Clinic Ventures: “The Revolutionary Changes in Healthcare Delivery: From Prevention to Rehabilitation and Everything in Between”

10:10-10:50 Jeroen Tas, Chief Innovation & Strategy Officer, Philips: “Creating the Future of Healthcare Through Digital Innovation”

+
10:50  –  11:20

Coffee Break

+
11:20  –  17:30
Hall A

Transformative Cancer Therapies

Chair: Prof. David Sidransky, MD, Johns Hopkins School of Medicine; Co-Founder and General Partner, Israel Biotech Fund

11:20-11:25 Opening by Chair

11:25-11:50 Gary Gordon, MD, PhD, Former Vice President, Global Oncology Development, AbbVie, Inc: “The 20 Year Journey of an Oncology Drug”

11:50-12:05 Prof. Elizabeth Croydon, Senior Clinical Director, Oncology – EU Clinical Development, Merck Sharp & Dohme: “MSD Immune-oncology Innovative Therapies”

12:05-12:20 Ruth Ben Yakar, PhD, Chief Executive Officer, BioSight: “Biosight Ltd. is Developing BST-236, a Novel Antimetabolite for First-line Treatment of Hematological Malignancies and Disorders”

12:20-12:35 Julian Adams, PhD, Chief Executive Officer, Gamida Cell: “Ex Vivo Expanded Cells to Treat Hematological Malignancies”

12:35-12:50 Baruch Schori, Chief Executive Officer, PTM Biosciences: “PTM Biosciences is Promoting Precision Medicine by Transforming Post-Translational Modifications into Novel Therapeutic Targets and Biomarkers for Disease Management”

12:50-13:05 Tehila Ben Moshe, PhD, Chief Executive Officer & Co-Founder, Biond Biologics: “Biond Biologics: From Innovative Science to the Clinic; Transforming the Treatment of Cancer”

13:05-13:20 Israel Isaac, Chief Executive Officer, Kitov Pharma: “NT-219, a First-in-class Dual Inhibitor of STAT3 and IRS1/2 is Overcoming Drug Resistance”

13:20-14:50 Lunch Break

14:50-15:10 Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH: “Bi-Specific Antibodies and Fusion Proteins in Cancer Therapy”

15:10-15:25 Prof. Dror Harats, CEO, Vascular Biogenics: “Turning ‘Cold’ Tumor into ‘Hot’ Tumor – Lessons from  VB-111, a Viral Immuno-oncology Agent and VB-611, a Novel Bi-specific Antibody”

15:25-15:40 Roni Mamluk, PhD, Chief Executive Officer, Ayala Pharmaceuticals: “Ayala Pharmaceuticals – Precision Oncology Targeted Therapy”

15:40-15:55 Frank Haluska, MD, PhD, Chief Executive Ofiicer, Anchiano Therapeutics: “Gene Therapy for Early Stage Bladder Cancer: The Pivotal Program with Inodiftagene”

15:55-16:10 Mark Schoenberg, MD, Chief Medical Officer, UroGen Pharma: “UroGen Pharma: Paradigm Changing Technology for Urologic Oncology”

16:10-16:25 Asher Nathan, CEO, NeoTX Therapeutics Ltd: “Selective T Cell Redirection (STR): A Second Generation Immunotherapy”

16:25-16:40 Amnon Peled, PhD, Chief Executive Officer, Biokine Therapeutics: “Development of First in Class High Affinity Small Molecule Antagonist of a Novel Cancer Target Critical for Tumor Cell Migration and Survival”

16:40-17:00 Concluding Remarks

+
11:20  –  17:05
Hall B

Personalized Medicine and Digital Health: Lessons Learned and Challenges Ahead

Co-chairs: Yair Schindel, MD, Co-Founder & Managing Partner, aMoon Fund; Prof. Varda Shalev, MD, MPA, Managing Director, Kahn-Sagol- Maccab Research and Innovation Institute at Maccabi Health Care Services

11:20-11:40 Fireside Chat – The Future Doctor, Patient and In-between
Prof. Varda Shalev, MD, MPA, Managing Director, Kahn-Sagol- Maccabi Research and Innovation Institute at Maccabi Health Care Services
Yair Schindel, MD, Co-Founder & Managing Partner, aMoon Fund

11:40-11:55 Oren Oz, CEO, Nuvo Group: “Reinventing Pregnancy Monitoring and Management for the 21st Century”

11:55-12:10 Seth Salpeter, CTO, Curesponse: “A Next Generation Platform for Definitive Treatment Answers in Personalized Cancer Medicine”

12:10-12:30 Michal Rozen-Zvi, Director, Healthcare Informatics, IBM Research: “Learn from Screening Data and Assessing Breast Cancer Risk”

12:30-12:45 Daniella Gilboa, Chief Scientific Officer and Co-Founder, AIVF: “Transforming IVF with the Power of Artificial Intelligence”

12:45-13:05 Uma Makhija, Business Development Lead, Digital Health, Otsuka Pharmaceuticals: “Pharma and Digital Therapeutics Partnerships – Opportunities and Challenges”

13:05-13:20 Lihi Segal, CEO, DayTwo: “Personalized Nutrition Recommendations for Normalizing Blood Glucose Levels Based on Microbiome, Medical and Personal Records”

13:20-14:50 Lunch Break

14:50-15:10 Prof. Eitan Friedman, MD, PhD, Director & Founder of The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Medical Center

15:10-15:25 Alex Melamud, CEO, Melcap Systems: “First Digital Health Affordable System for the Treatment of Overweight and Obesity for Billions”

15:25-15:40 Vince Gao, PhD, Founder & CEO, Govita Tech: “Association of Genetic and Metabolic Data Derived from Metabolic Pathways for Personalized Intervention of Chronic Diseases”

15:40-15:55 Erez Gavish, Co-Founder/CEO, 2breathe Technologies Ltd: “Can Digital Therapeutics Lower Sympathetic Overactivity?”

15:55-16:15 Elliot Menschik, MD, PhD, Global Head, Healthcare + Life Science Startups, Amazon Web Services: “Re:Inventing Healthcare – Glimpses of Digitally-enhanced, Data-driven Future”

16:15-16:30 Simona Di-Capua, Sr Dir GXR&D Tech & Process Design KFS, Teva: “3D Printing – A Novel Approach to Design and Manufacture Personalized Medicines”

16:30-16:45 Lior Wolff, Head of eHealth and Digital Wing at Clalit Health Services: “Clalit Health Services Expanding its Telemedicine Offering with TytoCare’s Physical Exam from Home”

16:45-17:05 Wade Ackerman, Partner, FDA Regulatory group, Co-Lead of Digital Health Initiative, Covington & Burling LLP: “Navigating the Evolving Regulation of Personalized Medicine and Digital Health”

+
11:20  –  17:20
Hall C

Cannabis’ Therapeutic Promise: Hope or Hype?

Co-chairs: Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem; Ayelet Torem, Adv, Partner, Hi-Tech & Venture Capital and Head of Global Markets, Amit, Pollak, Matalon & Co

11:20-11:45 Dorman Followwill, Senior Partner, Frost & Sullivan: “Outlook for Cannabis as Therapeutic Agent”

11:45-12:05 Prof. Hinanit Koltai, PhD, Agricultural Research Organization (ARO), Volcani Center: “Medical Cannabis: from Weed to Molecules to Drug Development”

12:05-12:25 Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem: “Improvement of CBD and THC Oral Bioavailability using Nano Delivery Systems”

12:25-12:45 Yossi Tam, The Hebrew University of Jerusalem: “Cannabinoid-Based Therapies: Lessons Learned from the Endocannabinoid System”

12:45-13:10 Prof. Raphael Mechoulam, PhD, Hebrew University of Jerusalem: “Cannabinoids: A Look Back and Ahead”

13:20:-14:50 Lunch Break

14:50-15:10 Medy Wiener, MD, Chief Medical Officer, BOL Pharma: “Drug/Cannabinoid Clinical Development Route – Same but Different”

15:10-15:25 Prof. Oded Shoseyov PhD, Co-founder and CSO, GemmaCert Ltd: “Remote Sensing of Cannabis; The First Steptowards Standardization and Closing the Learning Cycle”

15:25-15:40 Tamir Gedo, CEO, BOL Pharma: “The Winners and Losers of the Global Cannabis Industry”

15:40-15:55 Ascher Shmulewitz, CEO, Therapix Biosciences Ltd: “Therapix Biosciences Developing Cannabinoids of the Future”

15:55-16:10 Perry Davidson, CEO, Syqe Medical Ltd: “Medical Cannabis – The Green Elephants in the Room”

16:10-16:25 Dadi Segal, CEO, Panaxia Pharmaceutical Industries Ltd: “Panaxia – Manufacturing of Pharmaceutical Cannabis Products”

16:25-16:40 Taher Nassar, VP, Research, Bionanosim Ltd: “Bionanosim Ltd-Innovative Nano-Carriers for Improved Cannabis-BNS”

16:40-17:00 Prof. Itamar Raz, MD, Head, The Israeli National Diabetes Council: “Medical Cannabis treatment of Pain and Glycemic Control”

17:00-17:20 Ayelet Torem, Adv., Partner, Hi-Tech & Venture Capital and Head of Global Markets, Amit, Pollak, Matalon & Co: “Medical Cannabis Regulatory Overview”

 

SOURCE

http://kenes-exhibitions.com/biomed/program/?utm_source=All+Kenes+subscribers+%28divided+by+groups%29&utm_campaign=9ad5bcc465-MIXIII_BIOMED_201_GRAND_OPENING_INVITATION&utm_medium=email&utm_term=0_f956e1b94c-9ad5bcc465-227226585&ct=t(MIXIII_BIOMED_2019_GRAND_OPENING_INVITATION)&goal=0_f956e1b94c-9ad5bcc465-227226585&mc_cid=9ad5bcc465&mc_eid=0311bd1e30

Read Full Post »

Tweets and Retweets by @AVIVA1950 and by @pharma_BI for @USAIC and #USAIC2019 at the 13th Annual BioPharma & Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA

Posted in BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Informatics, Pharmaceutical R&D Investment on May 12, 2019| Leave a Comment »

Tweets and Retweets by @AVIVA1950 and by @pharma_BI for @USAIC and #USAIC2019 at the 13th Annual BioPharma & Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA

 

  1.  liked Tweets you were included in

    18 hours ago
      Talk  :  design now depends on  systems e.g. organelle delivery.  only wants accelerated approval not conditional approval. Surrogate markers critical for new trial design  

    4 other likes

  2.  liked your Tweets

    18 hours ago
            CAR-T Dr. Carl June, UPenn Moderator: Kucherlapati, Professor of Genetics,  China moved fast on CAR-T by National declaring priority government Investment regulatory strategy in China not FDA

    10 other likes

 

  1.   Retweeted

     May 10

    More

    Alise Reicin discusses endpoints needed in and effect of cost of in Panel Discussion morning Networking break

    1 retweet1 like
    Reply
    Retweeted

    Liked

    Direct message
  2.   Retweeted

     May 10

    More

    Alise Reicin Panel Discussion: best done as Basket&Umbrella trial; response rate 30-50% but Phase3 negative

    Translate Tweet

    1 retweet1 like
    Reply
    Retweeted

    Liked

    Direct message
  3.   Retweeted

     May 10

    More

    2019 Sector and in via

    4 retweets2 likes
    Reply
    Retweeted

    Liked

    View Tweet activity
  4.   Retweeted

     May 10

    More

    Dr. William Chin design challenges with newer in recruiting patients; use Basket&Umbrella Trial design Live

    1 retweet2 likes
    Reply
    Retweeted

    Liked

    Direct message
Direct message
 Retweeted

 May 9

More

On risk | benefit: Long term impacts of treatment may be present for the life of the patient

2 retweets1 like
Reply
Retweeted

Liked

Direct message
  5.   Retweeted

     May 9

    More

    Discussion of cyber security at panel moderated by – realization that everything is interconnected: risks to business-critical functions. Much to learn from FinTech & others’ prior experience.

    1 retweet1 like
    Reply
    Retweeted

    Liked

    Direct message
  6.   Retweeted

     May 9

    More

    Unexpected best thing about – at least three Zimbabweans in the crowd / on the stage.

    1 retweet2 likes
    Reply
    Retweeted

    Liked

    Direct message
  7.   Retweeted

     May 9

    More

    segueing into a discussion of safety, and risk tolerance. Prevention has a higher safety bar than treatment later in the disease process.

    1 retweet1 like
    Reply
    Retweeted

    Liked

    Direct message
    Show this thread
  8.   Retweeted

     May 9

    More

    Most humbling & touching moment: meeting an exec who nodded & teared up as I told him what we do His 9 yo child needs frequent contrast enhanced MRI scans for a rare disease. We felt like the smallest co at yet so important for hope & health

    2 retweets2 likes
    Reply
    Retweeted

    Liked

    Direct message
  9.  
  10.   Retweeted

     May 9

    More

    Great initiatives to bring CAR-T to India an automation to drug manufacturion

    Carl June believes we’re only a few years away from outpatient CAR therapies, with no need for intensive infrastructure with ICU.
    2 retweets2 likes
    Reply
    Retweeted

    Liked

    View Tweet activity

     May 11

    More

    Amazing moderator asking provoking question of best panel in responses by experts made known were different for competing rivals the aim is same best faster largest at lowest keeping maximized

    Dr. William Chin design challenges with newer in recruiting patients; use Basket&Umbrella Trial design Live  
    1 retweet1 like
    Reply
    Retweet

    Like

    View Tweet activity
  12.   Retweeted

     May 10

    More

    Dr. Bruce Chabner Talk: Old Phase 1,2,3 design not needed for & era based . very accommodating in Phase 1 trial design.

    2 retweets4 likes
    Reply
    Retweeted

    Liked

    Direct message
  13.   Retweeted

     May 10

    More

    Dr. Bruce Chabner panel discussion: selection based on new design paradigm; 40 drugs approved by accelerated approval for

    1 retweet1 like
    Reply
    Retweeted

    Liked

    Direct message
  14.   Retweeted

     May 10

    More

    Dr. Mace Rothenberg talks for approvals vary greatly over multiple countries makes issues of ong-term design and post approval reimbursement

    1 retweet2 likes
    Reply
    Retweeted

    Liked

    Direct message
  15.   Retweeted

     May 10

    More

    Talk : design now depends on systems e.g. organelle delivery. only wants accelerated approval not conditional approval. Surrogate markers critical for new trial design

    1 retweet2 likes
    Reply
    Retweeted

    Liked

    Direct message
  16.   Retweeted

     May 10

    More

    Dr. Rob Scott Panel Talk crisis in not in . Lowest investment in development. Physicians using SAME design for . use in trails increasing

    1 retweet4 likes
    Reply
    Retweeted

    Liked

    Direct message
  17.   Retweeted

     May 10

    More

    Dr. Rob Scott on design @usaic2019: Regulators as partners not barriers but burden of efficacy on . Can use advertising to increase recruitment as 70% willing participants live too far away so use &

    1 retweet2 likes
    Reply
    Retweeted

    Liked

    Direct message
  18.   Retweeted

     May 10

    More

    Dr. Rob Scott discusses recruitment and burdens : prefers to do in house & not use CRO as CRO less effective in monitoring trial

    1 retweet4 likes
    Reply
    Retweeted

    Liked

    Direct message
  19.   Retweeted

     May 9

    More

    “Some drug platforms are mature enough to fall under the practice of medicine” – Tim Yu of

    1 reply2 retweets2 likes
    Reply

    Retweeted

    Liked

    Direct message
    Show this thread
  20.   Retweeted

     May 9

    More

    Closing R&D strategies panel at is with NIBR’s Janssen’s and Takeda’s Andy Plump. Moderator Martin Mackay (now of newco Rallybio) asks: What are you most excited about?

    1 reply2 retweets2 likes
    Reply

    Retweeted

    Liked

    Direct message
    Show this thread
  21.   Retweeted

     May 9

    More

    Talk of indexed pricing model in the US may be a challenge for access to other parts of the world, says a speaker on rare disease panel

    1 retweet3 likes
    Reply
    Retweeted

    Liked

    Direct message
  22.   Retweeted

     May 9

    More

    The biggest problem that we have in the industry is the lack of empathy, says Chris Viehbacher

    2 retweets3 likes
    Reply
    Retweeted

    Liked

    Direct message
  23.   Retweeted

     May 9

    More

    Tim Yu’s example left a room full of seasoned biopharma R&D execs wowed. More background here:

    1 retweet6 likes
    Reply
    Retweeted

    Liked

    Direct message
    Show this thread
  24.   Retweeted

     Apr 15

    More

    (May 9, Boston) will feature plenary panel on Emerging R&D Strategies moderated by Dr. Martin Mackay, Co-Founder, Rallybio, with of , Andy Plump of , of Janssen, Michael Ehler of -> register today

    2 retweets3 likes
    Reply
    Retweeted

    Liked

    Direct message
  25.   Retweeted

     May 1

    More

    Check out my latest article: Where is Oncology Drug Development Heading Next? Hear From Top KOLs at 13th BioPharma Summit May 9, Boston via

    1 retweet3 likes
    Reply
    Retweeted

    Liked

    Direct message
  26.   Retweeted

     May 1

    More

    Check out my latest article: One in a Million: Emerging Trends in Rare Diseases at 13th annual BioPharma Summit- May 9, Boston via

    1 retweet2 likes
    Reply
    Retweeted

    Liked

    Direct message
  27.   Retweeted

     May 1

    More

    Check out my latest article: Chris Viehbacher, Gurnet Point Capital joins the USAIC Advisory Board. Please join Chris & other leaders at our annual BioPharma Summit, May 9, Boston via

    1 retweet2 likes
    Reply
    Retweeted

    Liked

    Direct message
  28.   Retweeted

     May 1

    More

    Check out my latest article: R&D Panel: BioPharma KOLs Debate R&D Strategies & Trends at 13th annual BioPharma Summit, May 9, Boston via

    2 retweets2 likes
    Reply
    Retweeted

    Liked

    Direct message
  29.   Retweeted

     May 1

    More

    Check out my latest article: What Does The Future Hold For Drug Development & Clinical Trials? Hear Predictions From Top Drug Developers at the 13th BioPharma Summit May Boston 9 via

    1 retweet3 likes
    Reply
    Retweeted

    Liked

    Direct message
  30.   Retweeted

     May 1

    More

    USAIC celebrates Biogen@40 via

    1 retweet3 likes
    Reply
    Retweeted

    Liked

    Direct message
  31.   Retweeted

     May 4

    More

    Value and Access – The Ongoing Debate.The BioPharma Summit will feature this special session. Join the discussion with BioPharma KOLs via

    5 retweets7 likes
    Reply
    Retweeted

    Liked

    Direct message
  32.   Retweeted

     May 6

    More

    BioPharma Manufacturing in the Future: Hear KOLs Debate the Challenges and Opportunities at the 13th annual BioPharma Summit, May 9, Boston via

    1 retweet2 likes
    Reply
    Retweeted

    Liked

    Direct message
  33.   Retweeted

     May 9

    More

    Our 13th Biopharma & Healthcare Summit has kicked off with introductory remarks from USAIC President Karun Rishi and emcee Dr. Andrew Plump, President of R&D for Takeda.

    5 retweets9 likes
    Reply
    Retweeted

    Liked

    Direct message
  34.   Retweeted

     May 9

    More

    The session is starting as I attend the focused on US-India bio-pharma healthcare summit. The focus is on and to deliver compelling affordable care with key role for technologies.

    2 retweets2 likes
    Reply
    Retweeted

    Liked

    Direct message
  35.   Retweeted

     May 9

    More

    Carl June believes we’re only a few years away from outpatient CAR therapies, with no need for intensive infrastructure with ICU.

    5 retweets12 likes
    Reply
    Retweeted

    Liked

    Direct message
  36.   Retweeted

     May 9

    More

    Dr. Maus ⁩ monitoring data from clinical trial is very important development of new targets multiple drugs multiple mechanism multiple specificities more modification to one cell contamination results

    3 retweets3 likes
    Reply
    Retweeted

    Liked

    View Tweet activity
  37.   Retweeted

     May 9

    More

    “Cancer is a collection of rare diseases” – , Director of Clinical Research, Cancer

    2 retweets2 likes
    Reply
    Retweeted

    Liked

    Direct message
  38.   Retweeted

     May 9

    More

    Sanat Chattopadhyay of US Merck says costs of manufacturing in US/Europe is significantly higher because technology deployed is ancient, both in small molecules and biologics.

    5 retweets12 likes
    Reply
    Retweeted

    Liked

    Direct message
  39.   Retweeted

     May 9

    More

    Rare disease taking center stage as technologies mature, panel moderated by CRISPR Therapeutics CEO Samarth Kulkarni

    3 retweets8 likes
    Reply
    Retweeted

    Liked

    Direct message
  40.   Retweeted

     May 9

    More
    Replying to  

    Enjoyed moderating the panel on manufacturing in the future as bio pharma companies explore ways to deliver drugs at affordable price and address access challenges. Digital innovation in manufacturing and supply chains will be key.

    2 retweets3 likes
    Reply
    Retweeted

    Liked

    Direct message
  41.   Retweeted

     May 9

    More

    Price is part of doing business…if you are not able to define value, you are sunk, says Chris Viehbacher Gurnet Point Capital

    2 replies4 retweets5 likes
    Reply

    Retweeted

    Liked

    Direct message
  42.   Retweeted

     May 9

    More

    All diseases are unique Your perspective changes when you or someone you love is diagnosed with a life-altering disease – rare diseases panel

    3 retweets3 likes
    Reply
    Retweeted

    Liked

    Direct message
  43.   Retweeted

     May 9

    More

    Arun Singhal, addl secretary, health ministry speaks about Ayushman Bharat, trade margin rationalisation, clinical trial rules at meeting

    2 retweets3 likes
    Reply
    Retweeted

    Liked

    Direct message
  44.   Retweeted

     May 9

    More

    Clinical trials in India picking up steadily, says Eswara Reddy, DCGI

    5 retweets8 likes
    Reply
    Retweeted

    Liked

    Direct message
  45.   Retweeted

     May 9

    More

    Regulators will “provide complete support” for clinical trials in India provided drug developers meet the new requirements – Drug Controller General of India Eswara Reddy

    6 retweets10 likes
    Reply
    Retweeted

    Liked

    Direct message
  46.   Retweeted

     May 9

    More

    discusses prevention and treatment of early disease e.g. precancer The challenge is to work out the commercial model says organize around prevention Early diagnosis / discovery of disease processes saves lives (’s raison d’etre)

    1 reply3 retweets3 likes
    Reply

    Retweeted

    Liked

    Direct message
    Show this thread

  47.  May 9

    More

    AMAZING EVENT @AVIVA11950 13th Annual & Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA via

    1 like
    Reply
    Retweet

    Like

    View Tweet activity

  48.  May 9

    More

    Dr. James Bradner, President, Novartis Institutes for BioMedical Research biophysical biochemical protein degradation – rewire disease cells with biomolecules combing propertitie of permiability of small molecules

    1 like
    Reply
    Retweet

    Like

    View Tweet activity

  49.  May 9

    More

    ⁦⁩ World PGD Growth of 4% in India 31%

    1 retweet2 likes
    Reply
    Retweet

    Liked

    View Tweet activity
  50.   Retweeted

     May 9

    More

    Takeda R&D Head Andy Plump asks question from audience to peers on stage: “I’ve been in the industry for 18 years and I can’t understand why a clinical trial costs so much. Why does it?”

    3 replies2 retweets7 likes
    Reply

    Retweeted

    Liked

    Direct message
  51.   Retweeted

     May 9

    More

    Manufacturing in the age of individualized medicine? We may need a completely different thinking for that says Paul Mckenzie, Biogen

    1 retweet10 likes
    Reply
    Retweeted

    Liked

    Direct message
  52.   Retweeted

     May 9

    More

    The so-called low-cost manufacturing edge of India will go away in a few years, says Hari Bhartia, Jubilant…being closer to the customer will be important

    4 replies8 retweets15 likes
    Reply

    Retweeted

    Liked

    Direct message
  53.   Retweeted

     May 9

    More

    Tricky question: getting patients to cancer centers to participate in clinical trials. Should patients be reimbursed for long travels and other expenses or will it be seen as an inducement?

    6 replies4 retweets15 likes
    Reply

    Retweeted

    Liked

    Direct message
  54.   Retweeted

     May 9

    More

    A chance to collaborate with my old colleague & friend ! -> another point from same panel: AbbVie CMO Rob Scott predicts tele-health solutions for clinical trial patients will be scalable soon

    Tricky question: getting patients to cancer centers to participate in clinical trials. Should patients be reimbursed for long travels and other expenses or will it be seen as an inducement?
    3 retweets5 likes
    Reply
    Retweeted

    Liked

    Direct message

  55.  May 9

    More
    Reply
    Retweet

    Like

    View Tweet activity
  56.   Retweeted

     May 9

    More

    Carl June: There are no CAR-T clinical trials in India. But says countries like India could eventually leapfrog to next gen (outpatient) cell therapy which will require less infrastructure + lower COG

    6 retweets5 likes
    Reply
    Retweeted

    Liked

    Direct message
    Show this thread
  57.   Retweeted

     May 9

    More

    The 13th Annual BioPharma & Healthcare Summit is being kicked off by Andrew Plump. In his opening remarks, he commented that we should feel privileged as attendees because not even or is invited to this meeting.

    1 retweet5 likes
    Reply
    Retweeted

    Liked

    Direct message
  58.   Retweeted

     May 9

    More

    A well-represented panel of scientists, CEOs and entrepreneurs discuss a range of discovery research from CAR-Ts to small molecules…on the same panel is Arjun Surya of Curadev that licensed a preclinical oncology lead to Takeda.

    5 retweets11 likes
    Reply
    Retweeted

    Liked

    Direct message

  59.  May 9

    More

    The promise of India is the largest democracy, the educated workforce the size of the market for therapeutics, access and price, reimbursement and regulation. DCGI the analogue of FDA is very active and innovated the challenge of 1.3 Billion a population of patients

    The session is starting as I attend the focused on US-India bio-pharma healthcare summit. The focus is on and to deliver compelling affordable care with key role for technologies.
    1 reply
    Reply

    Retweet

    Like

    View Tweet activity

  60.  May 9

    More

    Great Leader in immunotherapy, Carl June early inventor and endless commitment to patient a Pro for BioPharma

    Carl June endorses government-industry philanthropic partnerships to introduce next-generation cell therapy to countries like India
    Show this thread
    1 like
    Reply
    Retweet

    Like

    View Tweet activity

  61.  May 9

    More

    GREAT Conference of who is who in BioPharma, Boston at the top 500 startats of Biotech in Cambridge, MA ten years afo only a handful, boost by Novartis HQS in Cambridge, MA

    Our 13th Biopharma & Healthcare Summit has kicked off with introductory remarks from USAIC President Karun Rishi and emcee Dr. Andrew Plump, President of R&D for Takeda.
    Reply
    Retweet

    Like

    View Tweet activity

  62.  May 9

    More

    Liked the analogy of

    Andy Plump is hosting and called it the JPM of the East with cheaper hotel rates. We all chuckled. Then biotech investor Rajiv Kaul walks in and grabs a seat as Carl June takes the stage….
    Reply
    Retweet

    Like

Read Full Post »

2019 Biotechnology Sector and Artificial Intelligence in Healthcare

Posted in Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence - General, Artificial Intelligence Applications in Health Care, Artificial Intelligence in Health Care - Tools & Innovations, BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital on May 10, 2019| Leave a Comment »

2019 Biotechnology Sector and Artificial Intelligence in Healthcare

Reporter: Aviva Lev-Ari, PhD, RN

3.3.9

3.3.9   2019 Biotechnology Sector and Artificial Intelligence in Healthcare, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

AI Ushers in a New Era

The implications of AI, cloud-based technologies and increased R&D focus have lent a competitive edge to companies within the biotech space. The use of AI has gradually begun to revolutionize research activities in the industry as it can drastically reduce time and costs involved in developing life-saving drugs.

Let’s take a look at some instances on how AI is being used to advance in biotech. AiCure has developed an application that uses AI to govern if and at what time the patient takes a pill. Moreover, it is now being used regularly in many clinical trials. SOPHiA Genetics ‘ AI system is used for genomics analysis of next-generation sequencing data from hospitals and research institutions globally.

Moreover, Illumina ILMN released an open source artificial intelligence software for discovering previously overlooked noncoding mutations in patients with rare genetic diseases in the beginning of 2019.

In fact, J&J JNJ , Pfizer PFE and Novartis NVS have tie-ups with IBM’s Watson Health. Per the deals, the companies can use Watson Health’s AI solutions and applications for drug discovery and to accelerate cancer research efforts.

SOURCE

https://m.nasdaq.com/article/biotechnology-market-on-a-tear-5-etfs-in-spotlight-cm1128200

5 Biotechnology ETFs in Spotlight

, April 11, 2019, 03:33:00 PM EDT

The biotech industry has kept its promise for solid returns so far. The rally in some major biotechnology indexes reflects the same. In this context,

SOURCE

https://m.nasdaq.com/article/biotechnology-market-on-a-tear-5-etfs-in-spotlight-cm1128200

BioPharma

Novartis AG (NVS): Free Stock Analysis Report

Eli Lilly and Company (LLY): Free Stock Analysis Report

Roche Holding AG (RHHBY): Free Stock Analysis Report

Pfizer Inc. (PFE): Free Stock Analysis Report

Johnson & Johnson (JNJ): Free Stock Analysis Report

ALPS Medical Breakthroughs ETF (SBIO): ETF Research Reports

Principal Healthcare Innovators Index ETF (BTEC): ETF Research Reports

Virtus LifeSci Biotech Products ETF (BBP): ETF Research Reports

SPDR S&P Biotech ETF (XBI): ETF Research Reports

Spark Therapeutics, Inc. (ONCE): Free Stock Analysis Report

Illumina, Inc. (ILMN): Free Stock Analysis Report

ARK Genomic Revolution Multi-Sector ETF (ARKG): ETF Research Reports

SOURCE

To read this article on Zacks.com click here.

Zacks Investment Research

2019 M&A in Biotech

Mergers and acquisitions (M&As) are dominating the sector as sluggishness in mature products has forced companies to explore acquisitions to bolster their pipeline. The biggest deal of the year was Bristol-Myers’ acquisition offer of $74 billion to buy Celgene. Also, Eli Lilly and Company LLY has announced that it will take over Loxo Oncology for $8 billion to broaden its oncology suite to precision medicines or targeted therapies. (read: What’s Behind the Biotech ETF Rally to Start 2019? )

Several other large-cap pharma as well as bigger biotech companies are entering collaboration deals with smaller ones to boost their pipeline. Notably, Swiss pharma giant Roche Holdings RHHBY has bet big on U.S.-based gene therapy company Spark Therapeutics ONCE in an effort to strengthen its presence in gene therapy. Similarly, in order to develop gene therapies targeting rare indications, Biogen has offered to buy Nightstar Therapeutics.

Furthermore, in-licensing deals are consistently rising with bigwigs partnering with smaller and mid-sized players that own promising mid-to-late stage pipeline candidates or interesting technology.

SOURCE

https://m.nasdaq.com/article/biotechnology-market-on-a-tear-5-etfs-in-spotlight-cm1128200

Takeda-Novartis, Daiichi-AZ and more—FiercePharmaAsia
by Angus Liu

Takeda sells meds to Novartis and J&J; Daiichi’s AZ-shared HER2 antibody-drug conjugate hits key trial goal; Sun scouts for Chinese partner.
Takeda HQ
Novartis buys Takeda’s Xiidra, gets 400 staffers in $3.4B deal
by Angus Liu

Novartis hopes the deal, potentially worth $5.3 billion, could better position itself in front-of-the-eye therapies.
Asia Map
AZ, BeiGene, Kangmei and more—FiercePharmaAsia
by Angus Liu

AZ warns of slower China growth; BeiGene chief ranks among highest-paid biopharma CEOs; Kangmei faces delisting over huge accounting “error.”
Sanofi Pasteur HQ
After safety scare, Sanofi’s Dengvaxia nabs limited FDA nod
by Angus Liu

The FDA limited Dengvaxia to older children and teenagers living in endemic regions—and only if a diagnostic test confirms a prior dengue infection.
Takeda US facility
Takeda’s new Trintellix ad celebrates everyday wins
by Beth Snyder Bulik

Takeda highlights everyday joys in new TV ads for major depressive disorder treatment Trintellix.
ReputationSign
HIV drugmakers ViiV, Gilead top pharma reputation survey
by Beth Snyder Bulik

Pharma’s reputation is holding steady with patient groups with an annual study finding 41% giving pharma good marks, similar to 43% the year before.
Asia Map
PD-1 royalty dispute, Takeda and more—FiercePharmaAsia
by Angus Liu

Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.
Takeda scouts buyers for Latin American business: report
by Angus Liu

Takeda sold its Brazil-based unit Multilab right after it confirmed its plan to buy Shire, and now it’s reportedly mulling another sale in the region.
Woman typing on computer
Repackager recalls 40 lots of tainted losartan—News of Note
CDMOs Cambrex and Ajinomoto Bio-Pharma Services upgraded manufacturing plants, Takeda scored an albumin approval via its Shire deal, and more.
Darzalex
NICE limits coverage of J&J, Takeda myeloma combo
by Angus Liu

J&J’s Darzalex is on track to nab a second first-line myeloma nod in the U.S., but its reimbursement journey in England hasn’t been so smooth.

Other related 260 articles published in this Open Access Online Scientific Journal include the following:

https://pharmaceuticalintelligence.com/?s=Artificial+Intelligence

To access 260 articles:

GO TO Categories

Select CATEGORY

Artificial Intelligence per Ontology on this topic [multiple nested categories]

Read Full Post »

LIVE 13th Annual BioPharma and Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Drug Development Process, drug repurposing, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Informatics, Pharmaceutical R&D Investment, Pharmacodynamics and Pharmacokinetics, Pharmacogenomics, Pharmacovigilance, Value-based Drug Pricing on April 30, 2019| Leave a Comment »

LIVE 13th Annual BioPharma and Healthcare Summit, Thursday, May 9, 2019, Marriott Hotel, Cambridge, MA

Reporter: Aviva Lev-Ari, PhD, RN

 

http://www.usaindiachamber.org

8:40 AM – 9:10 AM Registration and Networking
9:10 AM – 9:20 AM Welcome address: Karun Rishi, President, USAIC

Opening comments: Dr Andrew Plump, President R&D and Director, Takeda Pharmaceuticals
9:20 AM – 9:40 AM Fireside Chat

  • Mark Abdoo, Acting Deputy Commissioner, U.S. Food and Drug Administration
  • Dr Eswara Reddy, Drug Controller General of India, Central Drug Control Organization

Moderator: Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.
9:40 AM – 10:00 AM Presentation on CAR (chimeric antigen receptor) T-cell Therapies
Dr. Carl June, Director of Translational Research, Abramson Cancer Center University of Pennsylvania Moderator: Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School
10:00 AM – 10:50 AM Panel Discussion: Oncology – The Emperor of BioPharma Development

Panelists:

Moderator: Dr. Christiana Bardon, Managing Director, MPM Capital
10:50 AM – 11:20 AM Networking Break
11:20 AM – 12:10 PM Panel Discussion: Future of Clinical Trials and Drug Development

Panelists:

Moderator: Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School
12:10 PM – 1:00 PM Panel Discussion: Manufacturing in the Future

Panelists:

  • Hari Bhartia, Founder and Co-Chairman, Jubilant Bhartia Group
  • Mark Abdoo, Acting Deputy Commissioner, U.S. Food and Drug Administration
  • Dr. Paul McKenzie, Executive Vice President, Pharma Operations & Technology, Biogen
  • Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.
  • Vinay Ranade, Chief Executive Officer, Reliance Life Sciences

Moderator: Professor N. Venkat Venkatraman, Boston University Questrom School of Business
1:00 PM – 1:50 PM Lunch
1:50 PM – 1:55 PM Video message from Suresh Prabhu, Hon’ble Minister of Commerce & Industry, Gov. of India
1:55 PM – 2:45 PM Panel Discussion: One in a million – Emerging trends in Rare Diseases

Panelists:

Moderator: Dr. Samarth Kulkarni, Chief Executive Officer, CRISPR Therapeutics
2:45 PM – 3:20 PM Networking & Tea Break
3:20 PM – 3:50 PM Fireside Chat: Value and Access – The ongoing debate

Moderator: Dr Andrew Plump, President R&D, Takeda Pharmaceuticals
3:50 PM – 4:10 PM India update on Clinical Trial Regulations

  • Arun Singhal, Additional Secretary, Ministry of Health & Family Welfare, India
  • Dr Eswara Reddy, Drug Controller General of India, Central Drug Control Organization
4:10 PM – 5:00 PM Panel Discussion: Research and Development Strategies and Trends

Panelists:

Moderator: Dr. Martin Mackay, Co-Founde, Rallybio
5:00 PM – 5:05 PM Closing Remarks
5:05 PM – 6:15 PM Cocktails & Networking Reception

Aviva Lev-Ari, PhD, RN & Leaders in Pharmaceutical Business Intelligence (LPBI) Group

will cover the event in Real Time

REAL TIME COVERAGE USING SOCIAL MEDIA

 

LIVE Images taken by @AVIVA1950

 

 

 

9:10 AM – 9:20 AM

Welcome address: Karun Rishi, President, USAIC

Opening comments: Dr Andrew Plump, President R&D and Director, Takeda Pharmaceuticals

  • tomorrow announcement @Shire
  • India 1.3Billion in India, each person is a potential patient in the largest democracy in the World
  • China – transformation takes place every day
  • The Patient and the Pricing of Drugs the biggest issue missing the ball dialoguing on Panel today

9:20 AM – 9:40 AM

Fireside Chat

  • Mark Abdoo, Acting Deputy Commissioner, U.S. Food and Drug Administration (FDA)
  • Dr Eswara Reddy, Drug Controller General of India (DCGI), Central Drug Control Organization

Moderator: Sanat Chattopadhyay, President, Merck Manufacturing Division; Merck & Co.

9:40 AM – 10:00 AM Presentation on CAR (chimeric antigen receptor) T-cell Therapies
Dr. Carl June, Director of Translational Research, Abramson Cancer Center University of Pennsylvania Moderator: Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

  • Video on child with recurrent twice of leukhimia
  • T-cell HIV Virus infect

 

10:00 AM – 10:50 AM

Panel Discussion: Oncology – The Emperor of BioPharma Development

Panelists:

  1. solid vs blood tumors
  2. T-Cells amplification microenvironment and biology
  3. PD-1 in combination therapies thousand Trials
  4. Biomarker allows to check response in conjunction with genomics data brings insights
  5. Tumors World, Biomarkers in Immuno oncology respond to PD-1 no response to other drug
  6. stratify patients
  1. Protein experimental data compound design from simulations of VIRTUAL compounds,
  2. how to incentivise to take on new innovations
  1. more that one single administration by injection
  2. response rates different even in one patient let alone among patients
  3. detection gene
  4. CAR-T glioblastoma
  5. pancreatic cancer good responses in combination therapies
  6. immunr repertoire biology so complex that biomarkers are limited

Moderator: Dr. Christiana Bardon, Managing Director, MPM Capital

  • 30% patinets with complete cure

10:50 AM – 11:20 AM Networking Break11:20 AM – 12:10 PM

Panel Discussion: Future of Clinical Trials and Drug Development

Panelists:

  1. endpoints need to be redefined it effect price of drug development
  2. in Oncology – Basket and Umbrellas Trial – two stufies approval for melanoma, biomarker
  3. Is response rate is 30% va 50% and Phase 3 is negative Kertuda when worked at Merck dose ranging last phase when response dropped from 60% to 30% in the case of Study C3
  4. 30% of the cost of the study – 30% was translational
  5. CRO model appropriate oversite vs douplication of tasks
  • Dr. Bruce Chabner, Director of Clinical Research, Mass General Hospital Cancer Center
  1. Old paradigm Phase 1,2,3 – off the board now, New drugs do not need the old paradigm
  2. Phase i1 changed if genomics is involved multiple cohorts at same time
  3. FDA play amazing role
  4. patient selection is key
  5. mutations in rare disease vs mutations in cancer
  6. immunotherapy and endogenic drugs with chemo in RENAL cancer
  7. check-points – lung cancer understood money spent to find responders
  8. HOW to select which cheno therapy — no improvement today vs past
  9. 40 drugs approved by accelerated approval one came back on the market
  10. Financial burden of being in a clinical trial
  11. Foundation gives money to Institutions to reimburse patients for flights, meals, acommodation, Pharma are reluctant to participants due to potential accusation of bias id Pharma pays Patients that participate in Clinical Trials
  1. FDA recognizes approval process – systems involved AFTER approval for reimbursement and monitoring after market
  2. regulatory by countires are different
  3. which factors are sacrifiable in the long tern in clinical trial design
  1. Safety – benefit risk is what physicians work with every day
  2. Drugs paradign of small molecules does not hold is you have a drug that deliver entire organelle – how you dose for half life how you prive the rate of replication in the body
  3. Surrogate markers
  4. Taking a drug off the market ->>  conditional approvals [approval can be taken back or require additional studies] not a favorable view of Pharma in the present to support Conditional approval vs accelerated approval

 

  1. speed
  2. differentiation from competition
  3. drug development in crisis is CVD not cancer, US and the rest of the world – lowest investment in drugs is CVD
  4. Studies designed by Physicians using SAME design
  5. need to create experts to use ML in the course of clinical trial design
  6. regulators as Partners not as Barriers
  7. Proof of efficacy is a burden on the developers of the drug not on the Regulatory
  8. Increase use of advertising to recruit
  9. 70% OF PATIENTS WILLING TO PARTICIPATE  lives to far from site of trials
  10. Telecommunication between administrators of study ans clinical Trials participants
  11. Back when I was at Pfizer, designing study – patients burden relieved more willingness to participate
  12. Preferrs to run studies in house vs use CRO they are not effective in monitoring like study run in house

Moderator: Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

  • Probability of success to clinic has not changed
  • challenge is design and execution in clinical trials
  • changes in drug modalities: RNA, DNA,
  • which combination to use
  • how to find the many patients needed
  • Basket and Umbrellas Trial

12:10 PM – 1:00 PM

Panel Discussion: Manufacturing in the Future

Panelists:

  • Hari Bhartia, Founder and Co-Chairman, Jubilant Bhartia Group
  1. supply change
  2. blockchain
  3. quality by design
  4. CPK
  5. productivity will go up variability will decrease
  6. manufacturng must happen in India
  7. Genetics price selection
  8. Secure system, data quality the data logic and the analytics
  9. infrastructure in manufacturing is not completed yet
  10. Training by augmented reality Turnover high in India
  11. cyber security – digitization and central control
  12. demonstration data offense
  • Mark Abdoo, Acting Deputy Commissioner, U.S. Food and Drug Administration
  1. next 10 years India and China will improve regulatory activities and match better the US requirements
  2. review foreign hosts
  3. skills and location of hosts:
  4. India: Standards and unannounced inspections and
  5. China: same
  6. Blockchain is experienced as experimentation at FDA across each all parts of the Agency
  • Dr. Paul McKenzie, Executive Vice President, Pharma Operations & Technology, Biogen
  1. raw material to patients: Pharma very slow than other industries Reliable needs be very high, relationships
  2. Hurrican in PortoRIco affected supply chain
  3. Reality, every one HAVE to be in China
  4. Platforming for each modality for Scaling out vs Scaling up
  5. diversify vs modality x
  6. build capacity and capabilities customization of ultra filtration different in two plants lowers standardizations
  7. Training on Demand, Virtually, documnetation needs to change to electronic
  8. Continueous manufacturing Academic contribution
  • Vinay Ranade, Chief Executive Officer, Reliance Life Sciences
  1. Pharma was slow in India the manufacturing
  2. infantile diarreha vaccine 70,000 in 4 years needs that drug,
  3. massive intellectual capital in India
  4. How to implement and make best use of data to improve processes
  5. cyber security was not experiences
  1. Phase 1 scaling out vs up – it is different in vaccine field
  2. ML, Block chain, supply chain and manufacturing will be adapted in supply chain
  3. Apply analytics and relationships in manufacturing
  4. obsolescence and upgrades
  5. capture data electronically
  6. cyber security can be a hazard hard to mitigate when all systems are down
  7. significant challenges in manufacturing and data security

Moderator: Professor N. Venkat Venkatraman, Boston University Questrom School of Business

  • How can Pharma become leaner
  • heterogenuious environment for production
  • cyber security

1:00 PM – 1:50 PMLunch1:50 PM – 1:55 PM Video message from Suresh Prabhu, Hon’ble Minister of Commerce & Industry, Gov. of India1:55 PM – 2:45 PM

Panel Discussion: One in a million – Emerging trends in Rare Diseases

Panelists:

  1. worked with Academic community on how to treat rare disease in the future
  1. Show clinical benefit and impact multiplemyeloma
  2. patients becoming activists
  3. access
  4. foundation by patients
  5. Patient to get cloud
  • Dr. Dhaval Patel, Executive Vice President  and Chief Scientific Officer, UCB
  1. if a modality will cure a disease justify innovation Model for payment: Mortgage Model
  2. Access INDEX pricing – US will benchmark the price in other parts of the world
  3. Gene therapy is not only got monognenic diseases but for
  4. decrease work involved in development of drugs
  • Dr. James Wilson, Director – Gene Therapy Program, University of Pennsylvania
  1. tension between physicians and development of the perfect drug.
  2. AV
  3. Protein replacement therapy repeated infusion gene therapy infrastructure develop in China for China, Develop in India for India vs develop in US for India or China
  4. Cost of manufacturing to decrease
  • Dr. Timothy Yu, Assistant Professor in Pediatrics, Harvard Medical School
  1. Scalability beyond the one case: the mechanism for the drug has generability for other aptients iwth same mutation the method has no limit
  2. Molecular type of mutation Spice Switching strategy, just-in-time manufacturing

Moderator: Dr. Samarth Kulkarni, Chief Executive Officer, CRISPR Therapeutics

  1. Rare diseases, potential for cure
  2. Academia, Hospitals, biotech
  3. commercial model of the disease

2:45 PM – 3:20 PMNetworking & Tea Break3:20 PM – 3:50 PM

Fireside Chat: Value and Access – The ongoing debate

  1. since 2003 testify in the House, against Canadian  David Brenner was asked about importation from Canada of breast cancer tamoxiphen at a lower price than in the US.
  2. From importation crisis to Obama Care – stable system Medicare Part D – drug coverage for Olderly
  3. After Obama – Price is part of doing business REBATES $100Billion the valur of REBATES
  4. Co-Insurance
  1. right for innovation will be preserved
  2. price increase
  3. give and take
  4. Co-pay – We need lower co-pay
  5. with current administration, sink finding the Well instead of Well funding the sick
  6. CHange is coming, co-pay will change
  1. Genzyme days vs 2019
  2. changes how drugs are priced?
  3. Flaws of the system:Gevernment induce prices that will change
  4. $800,000 drug is now $80 [ala Regeneron] – R&D was $2Billion
  5. CO-pay for hospital stay is lower than co-pay on drugs – 10% twice a year

Moderator: Dr Andrew Plump, President R&D, Takeda Pharmaceuticals

3:50 PM – 4:10 PM

India update on Clinical Trial Regulations

  • Arun Singhal, Additional Secretary, Ministry of Health & Family Welfare, India
  1. Each patient deserve access to healthcare in India
  2. experimenting
  • Dr Eswara Reddy, Drug Controller General of India, Central Drug Control Organization
  1. Time line for Application approval for drugs, if approved in another country 60 days
  2. Gov’t hospitals can import New drugs which have not been permitted in India

4:10 PM – 5:00 PM

Panel Discussion: Research and Development Strategies and Trends

Panelists:

  1. Neuroscience – Pharma understand biomarkers and now genetics
  2. Vaccines – across species in the animal WORLD
  1. Attempt not to tweak the PIPELINE: CVD, NEUROSCIENCE AND CANCER
  2. 485 Teams doing R&D convluence of interests to develop cure
  3. Modularity – BioMolecule — multimodality biophysical biochemical protein degradation – rewire disease cells with biomolecules combing propertitie of permiability of small molecules
  4. PHARMACOLOGICAL PREVENTION – biotech is inspiring only Pharma can solve
  1. immunooncology – mutation signature – marker protein signature — that group of diseases respond to
  2. colon cancer and multiple myeloma — understanding of the biology was deep

Moderator: Dr. Martin Mackay, Co-Founder, Rallybio

5:00 PM – 5:05 PM Closing Remarks

5:05 PM – 6:15 PM Cocktails & Networking Reception

Read Full Post »

LIVE Day Two: 2019 MassBio Annual Meeting, State of Possible Conference, Sonesta Hotel, Cambridge, March 28, 2019

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, Foundations for supporting Science and Education on March 28, 2019| Leave a Comment »

LIVE Day Two: 2019 MassBio Annual Meeting, State of Possible Conference, Sonesta Hotel, Cambridge, March 28, 2019

http://files.massbio.org/file/MassBio-State-Of-Possible-Conference-Agenda-Feb-22-2019.pdf

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

represented by Founder & Director, Aviva Lev-Ari, PhD, RN will cover this event in REAL TIME using Social Media

@pharma_BI

@AVIVA1950

#StateofPossible19

 

Day 2 Agenda – March 28, 2019

Possible Talk – The New Role of Police: Creating Non-Arrest Pathways to Treatment and Recovery Conference Wide 3/28/2019 8:45:00 AM 3/28/2019 9:00:00 AM
Future of Human Biology: How we are Already Evolving Ourselves Conference Wide 3/28/2019 9:00:00 AM 3/28/2019 9:45:00 AM
Possible Talk – The Evolution of the Investment Landscape to Support Future Innovations in Biotech Conference Wide 3/28/2019 9:45:00 AM 3/28/2019 10:00:00 AM
CFIUS: Proposed Rules Impacting Global Investments for Biotech Breakout – Business Track 3/28/2019 10:15:00 AM 3/28/2019 11:00:00 AM
Exploring the Possibilities of Microbiome Beyond GI Diseases Breakout – Science Track 3/28/2019 10:15:00 AM 3/28/2019 11:00:00 AM
Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies Breakout – Science Track 3/28/2019 11:30:00 AM 3/28/2019 12:15:00 PM
Financing Outlook for 2019-2020: Will the Bubble Burst? Breakout – Business Track 3/28/2019 11:30:00 AM 3/28/2019 12:15:00 PM
Lunch & Henri Termeer Innovative Leadership Award Conference Wide 3/28/2019 12:15:00 PM 3/28/2019 1:15:00 PM
Enabling Digital Health in the Healthcare Value Chain Conference Wide 3/28/2019 1:15:00 PM 3/28/2019 2:00:00 PM

Day 2 Agenda – March 28, 2019

8:15am – 8:45am: Breakfast

8:45am – 9:00am: Possible Talk

Possible Talk – The New Role of Police: Creating Non-Arrest Pathways to Treatment and Recovery

  • Treatment of excellence in opiods draws patients fro all the MA state to Boston Programs and from Outside of MA
  • 94% walking on the door receive referrals to treatment centers in MA
  • Prediction of the future of persistence of the phonomenon
  • Funding partnerships for reducing time in treatment due to efficacy and patients engagement
  • 500 police personnel are involved in Treatment available on Demand referral
  • Substance abuse programs that work using institutions as problem solvers
  • Urgent and important because people die every day

 

9:00am – 9:45am: Future of Human Biology: How we are Already Evolving Ourselves

Megan Thielking, STAT News

  • Ethics of Human germ line
  • George M. Church PhD, Professor of Genetics, Harvard Medical School
  1. Multiplexing and gene editing for reverse aging
  2. Doing to much by adding new forms somatic therapies feedback loop is long from young adults to aging
  3. Small pox: Gene therapy can becaome non expensive
  • Juan Enriquez, Managing Director, Excel Venture Management, Prof. @Harvard in Genomics and Manage Start up in Genomics
  1. conception – identical twins bred 20 years apart
  2. fetus external to body and male can have children
  • Greg Verdine, President, CEO & CSO, Board Member, LifeMine
  1. Embryos IVF,, fully sequence the embroy and
  2. Democratice technologies at high school age –
  3. Educators will play a role for informed decisions public education
  4. AI harder to democratize
  5. Ethics consideration in patient selection for certification

9:45am – 10:00am: Possible Talk – 

Possible Talk – The Evolution of the Investment Landscape to Support Future Innovations in Biotech

  • communication what Biotech do, how position biotech start up and how raise fund
  • Thematic Investing: ALPHA CURRENTS: AI, Medical Technologies, communication technologies
  • Mother test – Communication of thoughts

 

10:15am – 11:00am: CFIUS: Proposed Rules Impacting Global Investment for Biotech [Business Track]

  • Review committee foreign investment, purchasing entire company –
  • new regulation 8% foreign investment is the largest allowed share as equity position and
  • not to negatively affect cyber security and national security
  • In BioTech (i.e. gene editing technologies developed already overseas and all other ecosystems
  • Green Card Holder investor are not excempt of CFIUS is different that US Citizen Investors which are exempts
  • Vikas Goyal, Principal, S. R. One, GlasxoSK Limited
  • Linda Ji, Partner, McDermott Will & Emory
  1. Disclosure about the investment and investors
  2. neurotech, genetics, genomics
  3. Critical tech in Biotech: Foundational vs
  4. US EXPERT CONTROLLED Technology
  5. License needed for licensing US EXPERT CONTROLLED Technology
  6. CFIUS does not handle licensing
  • Lisa Schaefer, Director of Financial Services and Tax Policy, Biotechnology Innovation Organization (BIO)
  1. Expert controlled technology
  2. AI in Drug discovery -is emerging foundational technology
  • Johhy Hu – VC in Boston – FUND owners are Swiss & Italian citizenship

10:15am – 11:00am: Exploring the Possibilities of Microbiome Beyond GI Diseases [Science Track]

  • David Donabedian, Co-founder, CEO & Director, Axial Biotherapeutics
  • Justin Chakma, Head of BD and Strategy, Vedanta
  • Chris Howerton, Biotechnology Equity Analyst, Jeffries

11:00am – 11:30am: Networking Break 

11:30am – 12:15pm: Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies [Science Track]

  • Laura Indolfi, Founder & CEO, PanTher Therapeutics
  • Sven Karlsson, Co-Founder, CEO,& CBO, Platelet Biogenesis
  • Leslie Williams, Director, Founder, President and CEO, ImmusanT

11:30am – 12:15pm: Financing Outlook for 2019-2020: Will the Bubble Burst? [Business Track]

  • Bruce Booth, Partner, Atlas Ventures
  1. Great time of capital rich, 2018 2Q – largest M&A in Biotech
  2. staggering increase in funding
  3. capital is flowing not from VCs, bur large hedge funds and foreign investment – China related 40% and Abu Dabi invest in Biotech
  4. First IPO in 2012 was Biotech
  5. Investor more selective and descerned : Preclinical Phase 1
  6. 2009-2010 – cool off market
  7. 2019 at constructive market for growing companies

 

  • Kathy Bersteinsson, Morgan Stanley 
  1. $30 Billion in 2018
  2. 8 IPO, back
  3. 2019 will be constructive, capital for biotech ecosysytem 50Billion needed, @25 Billion is secured without convertibles
  4. back log of IPO for 2Q in 2019
  5. investors wish 30% returns – adjust IPO valuation some are 1.5 times and fees on top
  6. Investors willing to participate VC not participate in good markets
  7. Good IPO no VCs
  8. Oncology, Selling genes, CNS
  9. Maturing the crop takes time

 

  • Christine Brennan, Partner, MRL Ventures Fund, Merck US
  1. RNA landscape
  2. oncology

 

  • Barbara Dalton, Pfizer Ventures
  1. Neurosciences, Biogen failure, need for new drugs
  2. Newrodegeneration
  3. Venture group does invest in neuro because Pfizer left Neuro
  4. investment in IMMUNITY
  5. M&A pipeline to move the needle does not happens for small biotech
  6. Pfizer and all BIG Pharma do not but even though Tax Reform favor Big Pharma

 

  • Steve Wilcox, Lawyer – largest Biotech
  1. what is hot and not
  2. Option to Purchase is lousy for sellers you cap the upper bound

 

12:15pm – 1:15pm: Lunch and MassBio Innovation Award Presentation

  • Lita Nelson, fear of genetics lead to development of 1980s legislation ownership and Patent exploitation by institutions, Universities started to collect royalties from Tech Transfer, Gov’t supported 120 Billion in basic research since the 70s.
  • 200 Research Universities and Hospitals Tech Transfer Office research shows:
  • 6300 licenses granted
  • early investment in innovations – in MA, 30 years ago no Pharma in MA today 18 of 20 big Pharma are in Cambridge and other locations in mA
  • People: accelerate biotech faced scarce talent not scarce capital
  • networking – dense clusters in Cambridge
  • Cambridge is the envy of the World in BioTech

 

1:15pm – 2:00pm: Enabling Digital Health in the Healthcare Value Chain

Moderator: Hussain Mooraj, Delloitte

  • Jeff Elton, CEO, Concerto Health AI
  • Cluster of centers of excellence
  • Moderna, VP IT
  1. cross pollination =: CS + Biology form MIT
  2. Top management understand technologies in Biotech
  3. data collection
  4. blueprint to design a digital platform – from the start to do it right vs retrofits at later stage

 

  • Luba Greenwood, Google – Verily – IP was the asset in 2019 it is the DATA  not the IP – use of data to improve drug discovery
  1. Starting up a Biotech company
  2. Advice is available

 

  • ThermoFischer – R&D DIgital Science,
  • Pear Therapeutics, Brooke Paige, VP, Alliance ManagementBrooke Page

2:00pm – 2:30pm: Keynote Address

 

2:30pm – 3:00pm: Closing Networking Dessert Reception

@@@@@

8:15am – 8:45am: Breakfast

8:45am – 9:00am: Possible Talk

9:00am – 9:45am: Future of Human Biology: How we are Already Evolving Ourselves Humans began changing our environment early on through fire, agriculture and early medicines, and later with biopharmaceuticals and even CRISPR babies. Come hear futurists in human biology offer provocative thoughts on how we can wisely and ethically embrace next generation science to change our own DNA. – George M. Church Phd, Professor of Genetics, Harvard Medical School – Juan Enriquez, Managing Director, Excel Venture Management – Greg Verdine, President, CEO & CSO, Board Member, LifeMine

9:45am – 10:00am: Possible Talk

10:15am – 11:00am: CFIUS: Will New Regulatory Threats Reduce Global Investment in Biotech? [Business Track] CFIUS’ newly expanded scope and authority have the potential to severely disrupt investment in the U.S. biotech sector. A new federal law now includes biotechnology on a list of 27 “critical” industries where all foreign investment must be reviewed by the CFIUS office. With this new rule in place, questions abound about its impact on the biotech industry. Will raising money take longer? Will it deter foreign investors? Will it limit companies’ leverage during investment negotiations? Come hear legal, investor, and company experts discuss what companies and investors need to know about CFIUS’ impact on future investments in biotech companies. – Vikas Goyal, Principal, S. R. One, Limited – Linda Ji, Partner, McDermott Will & Emory – Lisa Schaefer, Director of Financial Services and Tax Policy, Biotechnology Innovation Organization (BIO)

10:15am – 11:00am: Exploring the Possibilities of Microbiome Beyond GI Diseases [Science Track] The specific balance of bacteria in your gut affects your digestive system, but new research also shows these bacteria affect your behavior, energy, heart, brain and other unexpected organ systems. Pioneers in microbiome expound on the possibilities. – David Donabedian, Co-founder, CEO & Director, Axial Biotherapeutics – Justin Chakma, Head of BD and Strategy, Vedanta – Chris Howerton, Biotechnology Equity Analyst, Jeffries

11:00am – 11:30am: Networking Break

11:30am – 12:15pm: Advancing from ‘R’ to ‘D’: Various Routes to Building Successful Clinical-stage Companies [Science Track] Massachusetts is the epicenter of startup creation for biotech, but it’s not always easy to go from research to commercialization. Come hear founders and industry leaders offer lessons learned on intelligently scaling your company amid rapid growth including when to partner, sell or IPO, or when to build or buy preclinical, manufacturing, and clinical development capabilities. – Laura Indolfi, Founder & CEO, PanTher Therapeutics – Sven Karlsson, Co-Founder, CEO,& CBO, Platelet Biogenesis – Leslie Williams, Director, Founder, President and CEO, ImmusanT

11:30am – 12:15pm: Financing Outlook for 2019-2020: Will the Bubble Burst? [Business Track] 2018 was a record year for biotech IPOs, the XBI hit an all-time high in August, and the FDA approved a record number of novel drugs. What will 2019 bring after late 2018’s many signals of a slowing market? Will M&A pick up? Can new IPOs continue at last year’s pace? How will public markets respond? Investment bankers, private equity, and industry leaders peer into their crystal ball to predict the financial outlook for the next few years. – Bruce Booth, Partner, Atlas Ventures

12:15pm – 1:15pm: Lunch and MassBio Innovation Award Presentation

1:15pm – 2:00pm: Enabling Digital Health in the Healthcare Value Chain At its core, digital technologies are increasingly critical in enabling the growth of biotechnology companies– from the development of better research and development insight engines, to the commercialization of next generation therapies via digital channels. This panel will explore best practices that enable the embedding of digital health technologies in the value chain for both life sciences companies, payers and providers.

2:00pm – 2:30pm: Keynote Address

2:30pm – 3:00pm: Closing Networking Dessert Reception

Read Full Post »

LIVE Day One: 2019 MassBio Annual Meeting, State of Possible Conference, Sonesta Hotel, Cambridge, March 27, 2019

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media on March 27, 2019| Leave a Comment »

LIVE Day One: 2019 MassBio Annual Meeting, State of Possible Conference, Sonesta Hotel, Cambridge, March 27, 2019

http://files.massbio.org/file/MassBio-State-Of-Possible-Conference-Agenda-Feb-22-2019.pdf

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

represented by Founder & Director, Aviva Lev-Ari, PhD, RN will cover this event in REAL TIME using Social Media

@pharma_BI

@AVIVA1950

#StateofPossible19

State of Possible Conference Day 1 Agenda – March 27, 2019

Session Title Session Type Start Time End Time
Breakfast & Registration 3/27/2019 8:15:00 AM 3/27/2019 8:45:00 AM
Breakfast 3/27/2019 8:15:00 AM 3/27/2019 8:45:00 AM
Keynote: State of the State of Possible: Where are we in the history of Biotech and What Lies Ahead? Conference Wide 3/27/2019 9:00:00 AM 3/27/2019 9:30:00 AM
‘Fireside Chat’ on RNAi and CRISPR: What Can the Past Teach Us and What Opportunities Await? Conference Wide 3/27/2019 9:30:00 AM 3/27/2019 10:15:00 AM
Possible Talk – The Possibilities of Gene Editing for Transforming the Practice of Medicine Conference Wide 3/27/2019 10:15:00 AM 3/27/2019 10:30:00 AM
Possible Talk – Leveraging Artificial Intelligence to Revolutionize Drug Discovery Conference Wide 3/27/2019 11:00:00 AM 3/27/2019 11:15:00 AM
Solving the Value Equation to Fix our Broken Healthcare System & Ensure Patient Access Conference Wide 3/27/2019 11:15:00 AM 3/27/2019 12:00:00 PM
Possible Talk: Opening Doors for the Future, a Patient’s Perspective Conference Wide 3/27/2019 12:00:00 PM 3/27/2019 12:15:00 PM
Early Stage Funding in the Era of Venture Creation Breakout – Business Track 3/27/2019 2:00:00 PM 3/27/2019 3:00:00 PM
From Academia to Commercialization: What’s the Threshold of Data Needed to Start a New Company? Breakout – Science Track 3/27/2019 2:00:00 PM 3/27/2019 3:00:00 PM
The Evolving Massachusetts Ecosystem: How Can we Continue to Sustain our Growth? Breakout – Business Track 3/27/2019 3:00:00 PM 3/27/2019 4:00:00 PM
Addressing the challenges of Large Population Diseases. Breakout – Science Track 3/27/2019 3:00:00 PM 3/27/2019 4:00:00 PM
The State of Neurodegenerative Disease: Drug Targets and Alternative, Patient-Centric Clinical Endpo Breakout – Science Track 3/27/2019 4:30:00 PM 3/27/2019 5:30:00 PM
Addressing the Opioid Crisis Breakout – Business Track 3/27/2019 4:30:00 PM 3/27/2019 5:30:00 PM
 

The State of Possible Celebration 3/27/2019 6:00:00 PM 3/27/2019 9:00:00 PM

 

Day 1 Agenda – March 27, 2019

8:45am – 9:00am: Welcome

9:00am – 9:30am: Keynote – State of the State of Possible: Where are we in the History of Biotech and What Lies Ahead?

  • Jeremy Levin, Chairman & CEO, Ovid Therapeutics, Inc.

No way to predict the future: rich and diverse, existential moment

  • impact of life expectancy
  • FDA in 2018 – record of Dr. Gottlieb in approval of new drugs
  • capital is flowing in LARGE amounts into innovations: new medical modalities: Gene therapy, immune oncology, RNA, CAR-T – 2500 clinical trials in immune oncology – product emerging as BIOSIMILARS
  • cell therapy, gene therapy
  • Health Insurers matters, consolidation, CIGNA partners with pharma
  • Insulin is $400 patients that can’t pay — covenant: Health Care must be universal for Economic growth considerations
  • Innovators part of the pie shrinks
  • Drug Pricing shifts the political balance
  • Bipartisan Pressure on the Pharma industry
  • WHAT IS COMING
  1. consolidations
  2. massive innovations
  3. innovations is essential – Financial burden
  4. CNS innovations – Alzermer’s Disease: Epilepsy,
  5. BIOSIMILARS: Crushing wave will create monopolies on OLD molecules PD!
  6. Organizational changes: Patient centricity using AI and precision
  7. Investors in Biotech in 2007 investors did not believe in immuno-oncology
  8. Pricing controversy – access and affordalitiry of cost out of pocket
  9. Bad democracy: if access is not to all
  10. CEO’s compensation need be tied to product innovations not to drug pricing
  11. IP Protection
  12. BIOTECH – matters: Sustainability if patient is the purpose
  13. Democracy is by all and for all

9:30am – 10:15am: ‘Fireside Chat’ on RNAi and CRISPR: What Can the Past Teach Us and What Opportunities Await?

Mike, Nikitas, Moderator

  • John Maraganore, Chief Executive Officer, Alnylam
  1. Tissue to benefit from RNA therapies only the beginning, not yet for cancer
  2. FDA has amazing scientists to continue Dr. Scott Gottlieb’s legacy
  3. Patients at the center and the Team move Science forward

Katrine Bosley, former Chief Executive Officer, Editas MedicineGenetic repair by gene deletions – as advances are achieved knowledge is shared cross projects on multiple indications

    1. regulators need to move faster as they see the innovations for tissue by gene medicine
    2. Dialog with FDA will continue Human germ line is NOT appropriate

10:15am – 10:30am: Possible Talk – Morgan Stanley

Possible Talk – The Possibilities of Gene Editing for Transforming the Practice of Medicine

Base Editing – Repair DNA

Creation of a new base editor – platform creation – platform to enable development – mammal cell lines

  • Cytidine Base Editor: (CxG -> TxA)
  • ApoE4 genetic factor fo rAlzheimer’s DIsease
  • Adenine Base Editor: (AxT ->GxC??)
  • Substrate specificity, delivery, product selectivity
  • @ BEAM Base editing as a Human Therapy 0 genetic disease faulty gene expression
  1. Gene correction,
  2. Gene regulation,
  3. Gene silencing,
  4. Gene reprogramming

Treating genetic disease ONE LETTER AT A TIME

10:30am – 11:00am: Networking Break 

11:00am – 11:15am: Possible Talk

Possible Talk – Leveraging Artificial Intelligence to Revolutionize Drug Discovery

  • Historical evolution of AI started on the 50s
  • Is Pharma ready for AI?
  • Publications on AI in Drug Discovery is th elargest growth in Publishing
  • Pharma Corporations, AI conpanies, Tech corporations
  • Potential contributions of AI to Human Biology

 

11:15am – 12:00pm: Solving the Value Equation to Fix our Broken Healthcare System & Ensure Patient Access

Margaux Hall, Moderator

  • Erin Mistry, Managing Director Pricing and Access, Syneos Health
  • Mike Bonney, Executive Chair, Kaleido Lifesciences
  1. Payers need to change their system for each new product they will reimburse for – IT system change
  2. Value based scheme are challenging due to data collections need by Payer to define contracts for VALUE definition and contract terms
  3. Will the value change on the next year is more enrolled as users?
  4. value-based constructs of therapeutics: population impact when patients start a given therapy – research shows that change in x yield favorable outcomes thus, approval of drug coverage by Payer  – ALWAYS have population effects
  5. Payors can loose cohorts and gain other cohorts by incentives
  6. Healthcare policies must be long term and not by Party election peril ti the Healthcare system
  7. Show progress that business strategy bring scoring on outcomes
  8. Saving life of patients, it is expensive, then it becomes free almost for developing countries, like vaccines and generics
  • Tamar Thompson, Executive Director, State Government Affairs & Federal Payment, Bristol-Myers Squibb
  1. pay less if pay cash without insurance vs pay insurance and pay co-pay — ?? affordability and gaining it fairly

12:00pm – 12:15pm: Possible Talk

Possible Talk: Opening Doors for the Future, a Patient’s Perspective

Make a change in life of Patients every day

12:15pm – 12:45pm: MassBio Presidential Address – Robert K. Coughlin, President and CEO, MassBio

12:45pm – 2:00pm: Lunch

2:00pm – 3:00pm: From Academia to Commercialization: What’s the Threshold of Data Needed to Start a New Company? [Science Track]

  • Irene Abrams, Vice President, Technology Development and New Ventures, Boston Children’s Hospital
  • Irena Ivanovska, Boston Site Head, Celdara Medical
  • Issi Rozen, Chief Business Officer, Broad Institute

2:00pm – 3:00pm: Early Stage Funding in the Era of Venture Creation [Business Track]

  • Todd Zion ex-Smart Cell, CEO
  • Paula Ragan, CEO, X4Pharmaceuticals
  • Rosemary Reilly, Partner, WilmerHale
  • Ramani Varanasi, CEO, X-Biotix

3:00pm – 4:00pm: Addressing the Challenges of Large Population Diseases [Science Track]

  • Calum MacRae, Vice Chair for Scientific Innovation, Brigham and Women’s Hospital, Harvard Medical School

3:00pm – 4:00pm: The Evolving Massachusetts Ecosystem: How Can we Continue to Sustain our Growth? [Business Track]

  • Tanisha Sullivan, Associate General Counsel, Industrial Affairs, Sanofi Genzyme
  • Doug Fambrough
  • Chandra Ramanthan
  • Johannes Fruehauf, Founder & CEO, LabCentral

4:00pm – 4:30pm: Networking Break 

4:30pm – 5:30pm: The State of Neurodegenerative Disease: Drug Targets & Alternative, Patient-Centric Clinical Endpoints [Science Track]

  • Robert Alexander, Vice President and Head, Global Clinical Science Neuroscience, Takeda
  • Joseph J. Higgins, MD FAAN, Vice President, Clinical Development, Huntington’s Disease Program Lead, Uniqure
  • John Torous, Director, Digital Psychiatry Division, Beth Israel Deaconess Medical Center
  • Sally Johnson, Biogen
  • Gilmore O”Neill, Serepta
  • Steve Wood – biomarkers (are LAB specific not regulated by FDA)
  • Ecosystem will continue to make bets, concept of POOLING FUNDING for bedding in paralllel and develop in parallel several therapeutic targets
  • Upside – investment will flow, Novertis and AztraZeneca joined funding on one development
  • Placing bets on Neurological diseases
  • neurogeneration of inherited diseases
  • Earlier intervention is better
  • target identification AUGMENTATION VS REMOVAL not clear what
  • Biogen measuring SNIPS Partnerships Academia and Industry

4:30pm – 5:30pm: Addressing the Opioid Crisis [Business Track]

  • Kerry Wentworth, Chief Regulatory Officer, Flexion Therapeutics

6:00pm – 9:00pm: State of Possible Celebration at the Museum of Science

Join us for drinks, food and networking at the Museum of Science! 

@@@@

8:45am – 9:00am: Welcome

9:00am – 9:30am: Keynote – State of the State of Possible: Where are we in the History of Biotech and What Lies Ahead? – Jeremy Levin, Chairman & CEO, Ovid Therapeutics, Inc.

9:30am – 10:15am: ‘Fireside Chat’ on RNAi and CRISPR: What Can the Past Teach Us and What Opportunities Await? Although researchers have been experimenting with gene therapy since the 1980s, 2018 was a major turning point in making these technologies a reality for patients. Not only was the first therapeutic using RNA interference (RNAi) approved last year, the first human clinical trials started for a CRISPR product. Come hear the two superstars of RNAi and CRISPR compare stories, lessons learned, thoughts on the future of gene editing, and more. – John Maraganore, Chief Executive Officer, Alnylam – Katrine Bosley, former Chief Executive Officer, Editas Medicine

10:15am – 10:30am: Possible Talk – Morgan Stanley

10:30am – 11:00am: Networking Break

11:00am – 11:15am: Possible Talk

11:15am – 12:00pm: Solving the Value Equation to Fix our Broken Healthcare System & Ensure Patient Access FDA approval used to mean access – but that’s no longer the case. More insurers are restricting access to new drugs, all at the expense of patients, using the argument that they do not bring enough value to the healthcare system. But what does value really mean? Experts in pricing and market access offer thoughts on how we might solve the value equation to improve patient access while continuing to reward innovation. – Erin Mistry, Managing Director Pricing and Access, Syneos Health – Mike Bonney, Executive Chair, Kaleido Lifesciences – Tamar Thompson, Executive Director, State Government Affairs & Federal Payment, Bristol-Myers Squibb

12:00pm – 12:15pm: Possible Talk

12:15pm – 12:45pm: MassBio Presidential Address – Robert K. Coughlin, President and CEO, MassBio

12:45pm – 2:00pm: Lunch

2:00pm – 3:00pm: From Academia to Commercialization: What’s the Threshold of Data Needed to Start a New Company? [Science Track] In 2012, Nature famously published a review by a former Amgen head of oncology research that 10% of landmark studies could not be reproduced. Company founders and initial investors must be certain that the academic work underpinning the foundational science and licensed patents are grounded in a sufficiently robust body of multiple lines of evidence can be reproduced. Serial founders and prolific professors discuss how to be sure initial scientific results are both fundable and can be advanced to “pharma grade”. – Irene Abrams, Vice President, Technology Development and New Ventures, Boston Children’s Hospital – Irena Ivanovska, Boston Site Head, Celdara Medical – Issi Rozen, Chief Business Officer, Broad Institute

2:00pm – 3:00pm: Early Stage Funding in the Era of Venture Creation [Business Track] Over the past decade, new biotech company creation has shifted away from investing in entrepreneurs to the venture creation model, where venture investors themselves assess an unmet medical need and create a company to address it. Yet, companies continue to spawn outside the venture creation model. Come hear experts discuss how they’ve raised money outside of the venture creation model through new sources of capital. – Paula Ragan, CEO, X4Pharmaceuticals – Rosemary Reilly, Partner, WilmerHale – Ramani Varanasi, CEO, X-Biotix

3:00pm – 4:00pm: Addressing the challenges of Large Population Diseases. [Science Track] As we better understand the genetics of disease, we can increasingly treat the underlying disease mechanisms rather than the superficial disease etiology. Biomarker testing toward improved drug effectiveness in defined sub-groups have made this a reality. Unlike oncology, where this concept is now mainstream, how might precision medicine apply to large patient populations like cardiovascular and neurodegenerative diseases? This panel will discuss the challenges and opportunities for precision medicine in these widespread maladies. – Calum MacRae, Vice Chair for Scientific Innovation, Brigham and Women’s Hospital, Harvard Medical School

3:00pm – 4:00pm: The Evolving Massachusetts Ecosystem: How Can we Continue to Sustain our Growth? [Business Track] Massachusetts is the #1 life sciences cluster in the world, in large part due to the collaboration and partnership among academia, industry, and government. The vibrant startup scene, along with a wealth of talent, is keeping and attracting big pharma and investors to the area, creating a collaborative environment unlike anywhere else. Yet, major challenges face the industry’s continued success in Massachusetts, from workforce development to sky-high rents to traffic. Come hear Massachusetts leaders discuss how the ecosystem is evolving and what we must do to remain on top. – Tanisha Sullivan, Associate General Counsel, Industrial Affairs, Sanofi Genzyme – Johannes Fruehauf, Founder & CEO, LabCentral

4:00pm – 4:30pm: Networking Break

4:30pm – 5:30pm: The State of Neurodegenerative Disease: Drug Targets & Alternative, Patient-Centric Clinical Endpoints [Science Track] Despite massive investments in research for diseases like Alzheimer’s and Parkinson’s, treatment options for patients are largely non-existent. ‘Soft’ clinical endpoints like Cognitive Impression scores are difficult to demonstrate statistical significance even when underlying biology is being modified. Industry and practicing clinicians share how they are introducing modern imaging and biomarker measurements as ‘harder’ endpoints to the FDA, along with including diverse patients in earlier trials to better predict large pivotal trials. – Robert Alexander, Vice President and Head, Global Clinical Science Neuroscience, Takeda – Joseph J. Higgins, MD FAAN, Vice President, Clinical Development, Huntington’s Disease Program Lead, Uniqure – John Torous, Director, Digital Psychiatry Division, Beth Israel Deaconess Medical Center 4:30pm – 5:30pm: Addressing the Opioid Crisis [Business Track] Pain treatment remains a pressing need, but opioid abuse grew by >10%, killing nearly 50,000 Americans in 2018. Despite decades in the spotlight, how can policy and law enforcement, medical providers and the biopharma industry come together to reverse the trend?

6:00pm – 9:00pm: State of Possible Celebration at the Museum of Science Join us for drinks, food and networking at the Museum of Science!

Read Full Post »

« Newer Posts - Older Posts »